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Human liver cancer is one of the deadliest cancers worldwide, with hepatocellular 
carcinoma (HCC) being the most common type. The neoplastic development of human 
HCCs is a complex multistage process, with heterogeneity in morphology and genetics 
that makes its ultimate clinical benefit negligible. Despite the relevance of HCC 
malignancy, a fundamental understanding of the molecular mechanisms of 
hepatocarcinogenesis is currently rather limited. As a potent proto-oncogene and bona 
fide central regulator of signal transduction pathways in many human cancers, Ras is at 
the leading edge of most tumorigenic events and is activated in nearly all HCC cases. 
Thus, targeting Ras signaling has emerged as a potential strategy to treat advanced HCC. 
However, the mechanism of Ras-induced liver cancer remains elusive and in vivo models 
that enable investigations of the important role of Ras in liver tumorigenesis are lacking. 
To address these problems, a constitutive transgenic zebrafish liver cancer model 
was first generated using a hepatocyte-specific promoter (fabp10) to target oncogenic 
krasV12 expression to the liver. Fusion with EGFP allowed visualization of the process of 
tumor development from early stages. Only high level of krasV12 expression initiated liver 
tumorigenesis. The krasV12 tumors showed progressive features from hyperplasia to 
invasive HCC which was accompanied by a loss of p53-dependent senescence response. 
HCC cells derived from this line also displayed transplantability. Transcriptomic analyses 
delineated several pathways and identified two conserved gene signatures accounting for 
HCC specificity and HCC progression in both zebrafish and human. These findings 
validated the potential of krasV12 transgenic fish in modeling human liver cancer. 
However, several limitations were found in this model such as low  HCC  penetrance and   
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premature lethality due to early Ras activation. 
Motivated by previous findings, another model allowing for liver-specific and 
inducible EGFP-krasV12 expression was generated using mifepristone-inducible strategy, 
which allowed to induce oncogene expression at any desirable time and to accelerate 
tumor onset. Robust and homogeneous HCC growth was achieved in 100% transgenics 
after 1 month induction. HCC was found to be “addicted” to Ras signaling for tumor 
maintenance as mifepristone withdrawal led to tumor regression via cell death. Targeting 
KrasV12 liver tumorigeneis via its downstream effectors, Raf/MEK/ERK and 
PI3K/AKT/mTOR, by chemical inhibitors significantly suppressed the over-growth of 
hyperplastic liver in EGFP-krasV12 larvae. Collectively, this model offered an effective 
and predictable liver cancer model for large-scale studies. 
It is well known that human cancer is usually initiated by a sporadic event of 
mutations occurring in a single or group of cells. Therefore, a third krasV12 liver cancer 
model was established using the mifepristone-inducible Cre/loxP approach. By exposure 
to mifepristone, Cre recombination was induced to permanently activate the liver-specific 
EGFP-krasV12 expression. Due to incomplete Cre-mediated recombination, a mosaic 
pattern of krasV12 expression resulted in broad liver tumor spectrum. Clonal proliferation 
of neoplastic cells expressing EGFP-krasV12 in normal-appearing liver can be observed in 
transgenic fish, offering a unique model to study spontaneous oncogenic mutations in 
humans. 
In summary, the krasV12 transgenic zebrafish is the first in vivo model unveilling 
molecular mechanisms underlying Ras-induced liver tumorigenesis that recapitulates 
typical hallmarks of human HCC. The two conserved HCC gene signatures identified in 
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this study might be useful as prognostic markers and potential therapeutic targets in 
human liver cancer. Adopting these krasV12 transgenic zebrafish model systems in which 
high incidence and consistent pattern of cancer progression are coupled with low 
maintenance costs of zebrafish would allow systematic study of liver cancer progression 




LIST OF TABLES 
Table 2.1 (p.37) Primer sequences used in quantitative real-time PCR 
 
Table 2.2 (p.38) Primer sequences used in genotyping PCR 
 
Table 3.1 (p.74) Potential HCC-specific gene signature restricted only to human 
HCC 
 
Table 3.2 (p.77) Potential liver cancer progression-associated gene signature 
 
Table 3.3 (p.78) Validation of differential gene expression in krasV12 transgenic fish 
by qRT-PCR 
 
Table 3.4 (p.105) Histopathologic findings in Triple-Tg zebrafish overexpressing 
krasV12 since 1-month-old 
 
Table 4.1 (p.124) Comparison of the three krasV12-induced liver cancer models using 





LIST OF FIGURES 
Figure 1.1 (p.4) Multi-stage process of hepatocarcinogenesis 
 
Figure 1.2 (p.9)  Advantages of zebrafish as a powerful model organism for cancer 
research 
 
Figure 1.3 (p.19) Distribution of KRAS somatic mutation frequency in human 
cancers 
 
Figure 2.1 (p.28) Alignment of human and zebrafish KrasV12 amino acid sequences 
 
Figure 3.1 (p.49) Generation and characterization of Tg(fabp10:EGFP-krasV12) 
transgenic zebrafish  
 
Figure 3.2 (p.50) Morphological development of liver in transgenic fish expressing 
EGFP-krasV12 
 
Figure 3.3 (p.53) Premature lethality caused by high level of krasV12 expression in 
transgenic zebrafish. 
 
Figure 3.4 (p.54) Liver tumors progression in krasV12 transgenic zebrafish 
 
Figure 3.5 (p.57) Growth of transplanted krasV12 liver tumors in WT recipients 
 
Figure 3.6 (p.60) Hyperactivation of the mitogen-activated protein kinase (MAPK) 
signaling pathway in krasV12transgenic zebrafish 
 
Figure 3.7 (p.63) Activation of the Wnt/β-catenin pathway during krasV12liver 
tumorigenesis 
 
Figure 3.8 (p.66) KrasV12-induced p53-dependent senescence in the pre-neoplastic 
liver 
 
Figure 3.9 (p.69) Flowchart of microarray data analysis 
 
Figure 3.10 (p.72) GSEA identification of conserved gene signatures common 
between zebrafish and human HCC 
 
Figure 3.11 (p.81) Mifepristone-inducible liver-specific oncogenic krasV12expression 
in transgenic zebrafish 
 
Figure 3.12 (p.85) Dosage-dependent induction of krasV12 expression and liver tumor 
induction and regression 
 




Figure 3.14 (p.90) Roles of Raf/MEK/ERK and PI3K/AKT/mTOR pathways during 
krasV12 tumor progression and regression 
 
Figure 3.15 (p.93) Suppression of liver tumorigenesis by inhibition of Raf/MEK/ERK 
and PI3K/AKT/mTOR pathways 
 
Figure 3.16 (p.96) Strategies for the mifepristone-induced Cre-mediated conditional 
expression of krasV12 in transgenic zebrafish 
 
Figure 3.17 (p.99) Optimization of Cre expression mediated by mifepristone in 1-
month-old transgenic fish 
 
Figure 3.18 (p.102) Mosaic pattern of Cre-mediated activation of EGFP-KrasV12 in 
Triple-Tg fish 
 
Figure 3.19 (p.103) Heterogeneous liver tumors induced by oncogenic krasV12 
 
Figure 3.20 (p.104) Early induction of krasV12 caused high penetrance of liver tumors 
 
Figure 3.21 (p.107) Deregulation of ERK and Wnt/β-catenin pathways during krasV12-
induced liver tumor progression 
 
Figure 4.1 (p.112) Proposed mechanism of Ras-induced liver tumorigenesis in 
transgenic zebrafish model 
 
Figure 4.2 (p.117) Tumorigenesis and tumor regression in the mifepristone-inducible 




LIST OF COMMON ABBREVIATIONS 
Ac/Ds Activator/Dissociation transposon system 
bp base pair 
cryB crystallin beta B  
DMSO  dimethylsulphoxide 
DNA deoxyribonucleic acid 
Driver/Cre-effector double transgenic zebrafish harboring the Liver-driver and Cre-
effector constructs 
Driver/Ras-effector double transgenic zebrafish harboring the Liver-driver and 
Ras-effector constructs 
dpi day(s) post-injection 
dpf day(s) post-fertilization 
EGFP  enhanced green fluorescent protein 
EGFP-KrasV12 fusion protein of N-terminal EGFP and C-terminal zebrafish 
KrasV12 
ENU ethylnitrosourea 
fabp10 fatty-acid binding protein 10  
FWER family-wise error rate 
GSEA gene set enrichment analysis 
h hour(s) 
HB hepatoblastoma 
HCA hepatocellular adenoma 
HCC hepatocellular carcinoma 
 XV 
 
HL hyperplastic liver 
kb kilobase pair 
mpf month(s) post-fertilization 
mRNA messenger ribonucleic acid 
NES normalized enrichment score 
NTg transgenic zebrafish with normal liver 
NWT wild-type zebrafish with normal liver 
OIS oncogene-induced senescence  
PCR polymerasechain reaction 
qRT-PCR quantitative real-time PCR 
RNA ribonucleic acid 
RT-PCR reverse transcriptase PCR 
TILLING  targeting-induced local lesions in genomes 
Triple-Tg triple transgenic zebrafish harboring three different constructs 
including Liver-driver, Cre-effector and LChL-Ras  
TUNEL  terminal deoxynucleotidyl transferase dUTP nick end labeling 
wpf week(s) post-fertilization 
wpi week(s) post-induction 













1.1 Introduction to human liver cancer 
1.1.1 Incidence, epidemiology and risk factors 
Human liver cancer ranks as the fifth most prevalent malignancy and the third leading 
cause of cancer mortalities worldwide with only 10% five-year survival rates (Villanueva 
and Llovet, 2011). Liver cancer comprises of diverse, histologically distinct primary 
hepatic neoplasms, with hepatocellular carcinoma (HCC) as the most common type 
accounting for approximately 83% of all cases. The incidence of new HCC cases is 
estimated to be 0.5-1 million globally per year which causes approximately 0.6 million 
annual deaths (Gomaa et al., 2008). HCC incidence increases with age and also generally 
affects men more frequently than women. Although HCC affects all segments of the 
world population, over 80% of HCC occurs in developing countries which lack 
infrastructure for the management of this disease. Indeed, the highest HCC incidence was 
reported in Asia and Africa (>20 cases per 100,000 of the population) (Nordenstedt et al., 
2010). The incidence of HCC also varies between different geographic regions, as well as 
countries that reflect regional differences in the prevalence of specific etiological factors 
and ethnicity. In Europe and the USA, HCC has recently gained major attention due to its 
doubling incidence during the past two decades (El-Serag and Rudolph, 2007). The major 
known factors associated with HCC development include hepatitis B viral (HBV) and/or 
C (HCV) infection, alcoholic abuse, aflatoxin B1 exposure and cirrhosis-inducing 
conditions. As such, over 80% of HCC are attributed to chronic HBV and HCV 
infections (Yang and Roberts, 2010). HBV-induced hepatocarcinogenesis contributes to 
most HCC in certain regions of Asia and Africa where HBV is epidemic. On the other 
hand, HCV is the most significant risk factor for HCC in Western Europe and North 




Due to various etiological factors, human HCCs are morphologically and 
genetically heterogeneous, which makes its molecular pathogenesis complex involving 
genetic and epigenetic events. Therefore, the molecular mechanisms underlying 
hepatocellular carcinogenesis are still poorly understood. As for most types of cancer, 
liver tumorigenesis is a multi-stage process starting from hyperplastic nodules to 
dysplasia, and eventually benign and malignant full-blown HCC (Figure 1.1) (Farazi and 
DePinho, 2006). Despite its severity, there are limited therapeutic options for HCC and 
the ultimate clinical benefits remain negligible. Thus, more research needs to be 
conducted to fully understand HCC for improvement of enhanced treatments to control 





Figure 1.1 Multi-stage process of hepatocarcinogenesis. The proposed 
histopathological progression and common molecular features of HCC caused by 
different etiologies including hepatitis B or C virus (HBV or HCV), aflatoxin B1 and 
alcohol were shown. After hepatic injury was triggered by any one of risk factors, there 
was necrosis followed by hepatocyte proliferation. Continuous cycles of this process led 
to liver cirrhosis with the formation of abnormal liver nodules. Consequently, these 
nodules progressed to hyperplasia, dysplasia and ultimately hepatocellular carcinoma 
(HCC), which could be further classified into subgroups containing well differentiated, 
moderately differentiated and poorly differentiated tumor cells. Loss-of-function p53 and 
genomic instability were found to involve during HCC progression. This figure was 





1.1.2 Current trends in therapeutic strategies of human HCC 
Treatment options for early HCC include liver transplantation, resection or local radiation 
therapies. Although the main curative treatment for HCC is surgical resection, there is 
limited improvement to the availability of alternative treatments (Llovet and Bruix, 
2008). In fact, the tumor recurrence rate is frequently high and most HCC patients are 
diagnosed at relative late stages when the above treatment and chemotherapeutic options 
are inapplicable. Another major obstacle for treatment of this cancer is the fact that HCC 
is regularly resistant to conventional chemotherapy and radiotherapy. Furthermore, there 
is significant clinical and genetic heterogeneity among HCCs of different etiologies and 
standard treatments may therefore not work for all HCC cases (Villanueva and Llovet, 
2011). Thus, HCC intervention is still a big challenge and a complete understanding of 
the common molecular events leading to the initiation and progression of HCC is a 
prerequisite to the prognosis and discovery of early treatment for this cancer. In the past 
few years, considerable progress has been made in elucidating some of the molecular 
steps leading to the development of HCC. Currently, two main pathogenic mechanisms 
prevail during hepatocarcinogenesis, including cirrhosis associated with sustained cycles 
of hepatic necrosis–inflammation–regeneration caused by hepatitis infection or toxins, 
and mutations occurring in single or multiple oncogenes or tumor suppressor genes 
(Farazi and DePinho, 2006). Both mechanisms have been linked with alterations in 
several important signaling pathways. These key signal transduction pathways that have 
been implicated in the development and progression of HCC include those mediated by 
VEGF, IGF and EGFR, and the Raf/MEK/ERK, PI3K/AKT, Wnt/β-catenin and 




different etiological factors has created a potential avenue for anticancer drug discovery 
or molecular targeted therapies for HCC. Unlike conventional cytotoxic chemotherapy, 
targeted therapies are designed to inhibit tumor-specific molecular structures or activation 
of pathways that are involved in the development of HCC. Two main classes of targeted 
therapies are currently available, namely monoclonal antibodies and small-molecular 
inhibitors (Spangenberg et al., 2009). Strikingly, Sorafenib, a multi-target compound 
which effectively blocks both Ras/Raf/MEK/ERK and VEGF pathways, is the only drug 
approved for the treatment of advanced HCC (Villanueva and Llovet, 2011). The survival 
benefit obtained in advanced HCC patients treated with Sorafenib was 10.7 months 
versus 7.9 months in the placebo group. The advent of Sorafenib and molecular targeted 
therapies represented the dawn of a new era in the complex management of HCC, which 
should be complemented with other molecular approaches. Future research is expected in 
the development of more model systems as well as to study HCC progression and 
identify new oncogenes as targets for therapies, and to test new compounds to block 
currently undruggable pathways or several other simultaneous pathways through high-
throughput screening.  
 
1.2 Zebrafish as a liver cancer model 
Animal models have been widely used in biomedical research to define the pathogenesis 
of cancer and as in vivo systems for developing and testing new therapies. Indeed, drug 
discovery involves a complex process of biomedical and cellular assays, with final 
validation in mammalian models before ultimate test in humans (Zon and Peterson, 




various features, such as its entirely sequenced genome and the genetic and biological 
similarities to human (Fausto and Campbell, 2010). Furthermore, the mouse together with 
other mammalian models including rats has made the prediction of drug efficacy and 
toxicity more reliable. However, these animal models tend to be costly, laborious, require 
large quantities of precious compounds and are unfeasible for large-scale studies 
(Sharpless and DePinho, 2006). In this context, the zebrafish (Danio rerio) has come to 
attention as an economic model which generally mimics human diseases and offers the 
ability to quickly and inexpensively test the efficacy and safety of compound libraries 
(Amatruda and Patton, 2008; Liu and Leach, 2011; Zon and Peterson, 2005). 
 
1.2.1 Advantageous use of the zebrafish in research 
The zebrafish is a powerful vertebrate model system not only in developmental biology, 
but also in biomedical research (Lieschke and Currie, 2007). This small (3-4 cm) 
freshwater tropical teleost vertebrate is originally from the Ganges River in India. The 
history of zebrafish as an experimental model began as early as 1980s when George 
Streisinger and colleagues established pure strains of zebrafish and pioneered its utility as 
a model organism to study embryogenesis (Streisinger et al., 1981). The initial focus of 
zebrafish research was on developmental biology reflecting its unique advantages such as 
short life cycle, optical clarity of embryos and larvae, and embryological manipulability. 
Zebrafish reaches sexual maturity by three months of age with high fecundity. A breeding 
pair can produce large numbers (100-200) of embryos in one morning. The growth and 
development of embryonic zebrafish are rapid, finishing gastrulation within 10 hours and 




attractive feature to the developmental biologist is that the transparent embryos develop 
outside the mother, thus allowing noninvasive visualization and ploidy manipulation for 
genetic analysis from the point of fertilization (Lieschke and Currie, 2007). Zebrafish 
embryos are also permeable to many small molecules and hence become a potential 
whole-animal vertebrate model for chemical genomics. In the past decade, several 
additional tools have been developed that greatly increases the utility of the zebrafish as 
an experimental model. Indeed, the zebrafish genome sequencing project is almost-
completed, which facilitated genomic studies for gene expression profiling (Lieschke and 
Currie, 2007). On the other hand, whole-mount in situ hybridization permits the analysis 
of gene transcription, whereas injection of morpholino antisense oligonucleotides 
(morpholinos) allows the study of gene function robustly in zebrafish embryos. In 
addition, techniques for generating transgenic zebrafish, such as cloning, mutagenesis, 
transgenesis and microinjection, further strengthen the use of zebrafish. Recently, there is 
increased generation and analysis of zebrafish models of human diseases (Amatruda and 
Patton, 2008; Liu and Leach, 2011). Owing to the ease of housing maintenance, short 
generation time and fecundity, zebrafish studies are cost-effective and provide 
advantages over other models in high-throughput small molecule screening. All these key 






Figure 1.2 Advantages of zebrafish as a powerful model organism for cancer 
research. Similar to flies and worms, zebrafish embryos are transparent and produced in 
large numbers which are suitable for genetic and chemical screens as well as 
experimental manipulation. In addition, its small size and rapid generation time facilitates 
genetic studies and offers economic benefit. Like mammals, zebrafish possesses 
vertebrate anatomy, physiology, and tumor biology. This figure was adapted from 





1.2.2 Modeling human diseases using zebrafish 
Realizing the full potential of the zebrafish model in studying disease genetics will 
require the generation of transgenic fish with alterations in specific genes. Over the past 
two decades, numerous methods became available for genetic manipulation of zebrafish, 
including both forward and reverse genetic approaches (Amatruda and Patton, 2008; 
Lieschke and Currie, 2007). 
Forward genetics. The zebrafish is best known for its effectiveness as a forward 
genetics tool. In this method, chemical mutagens, irradiation or insertional mutagens such 
as retroviruses or transposons were used to introduce random mutations into the genome. 
The progeny of mutagenized adult zebrafish are screened to obtain an abnormal 
phenotype harboring that particular genetic mutation. The underlying genetic mutation is 
then identified through genetic mapping, sequence analysis and phenotype validation. To 
date, several large-scale chemical screens using ethylnitrosourea (ENU), which induces 
mainly point mutations, have generated over 2,000 phenotypic mutants (Amatruda and 
Patton, 2008). Many of these mutated zebrafish genes are also orthologous to human 
genes causing congenital diseases with phenotypic similarities. Zebrafish mutants 
achieved through these screens recapitulate several aspects of human hematopoietic, 
cardiovascular, visual and kidney disorders. For example, in both zebrafish and human, 
ttn mutations lead to cardiomyopathy; tbx5 mutations cause congenitial heart defects and 
kcnh2 mutations result in arrhythmias (Zon and Peterson, 2005). As multiple mutations 
occur in cancer, it is challenging to perform forward screens with cancer as the assay 
endpoint. However, deregulations of cancer-related pathways can easily be detected in 




senescence and TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) 
assay for cell death. Screening for cancer-susceptibility genes in zebrafish is relatively 
straightforward.  
Reverse genetics and transgenesis. Reverse genetic approaches permit the direct 
assessment of known genes in the process of disease or cancer development. A robust 
and reliable reverse genetics strategy known as targeting-induced local lesions in 
genomes (TILLING) has been developed to conduct target-selected mutagenesis in 
zebrafish (Amatruda and Patton, 2008). Just as in a forward genetic screen, this method 
involves screening of large populations of mutagenized fish for the identification of gain- 
or loss-of-function in any genes of interest (Lieschke and Currie, 2007). To date, several 
key tumor suppressor null mutants such as tp53 and pten have been identified through 
TILLING (Berghmans et al., 2005; Faucherre et al., 2008). In embryonic and larval 
zebrafish, reverse genetic analysis is also facilitated by transient gene expression assays. 
Microinjection of either mRNA or morpholinos respectively produces transient gene 
overexpression or knockdown. These methods provide a quick approach to examine the 
potential genetic interactions or therapeutic effects of gain- or loss-of-function of genes. 
A recent technique has also been developed for targeted gene inactivation using 
engineered zinc finger nuclease to induce directed mutation (Sander et al., 2011). 
Another alternative for studying gene function is the generation of transgenic zebrafish 
by injecting a DNA construct into one-cell embryos. This method is especially useful for 
expressing an oncogenic form of a gene under the control of a tissue-specific promoter. 
The efficiency of transgenic technique has been dramatically improved by the 




integration of a transgene into the fish genome (Emelyanov et al., 2006; Kawakami et al., 
2004). Given the transparency of zebrafish embryos, such transgenes are frequently 
coupled to a fluorescent tag such as EGFP or mCherry, to monitor transgene expression 
in vivo and allow the process of tumorigenesis to be captured in real time by microscopy. 
In addition, availability of clonal zebrafish lines as well as transparent adult zebrafish 
enable live visualization of tumor engraftment, proliferation, and distant metastases 
during transplantation (Mizgirev and Revskoy, 2010; White et al., 2008). Over the past 
few years, a number of transgenic zebrafish models for tumorigenesis have been 
described including the Myc-induced leukemia, BRAFV600F-induced melanoma, and 
KRASG12D-induced rhabdomyosarcoma and pancreatic adenocarcinoma (Langenau et al., 
2003; Langenau et al., 2007; Liu and Leach, 2011; Patton et al., 2005). Beyond modeling 
human diseases, these models can also be used to design efficient and practical 
mutational screens for mutations that affect different aspects of tumorigenesis.  
From a clinical perspective, one of the most practical contributions that a disease 
model can make is to improve diagnosis and therapy. Other than understanding disease 
mechanisms and identifying therapeutic targets, zebrafish disease models offer an 
attractive platform for drug discovery. The zebrafish is cost-effective and highly fecund. 
The small size of zebrafish embryos allows them to be arrayed into a 96-well plate with 
each well containing 100-200 µl of water, thus minimizing the amount of drug needed 
(Huang et al., 2011). In addition, the zebrafish is promising for whole-animal functional 
analyses that also assess how drugs may perturb fetal development. By exploiting these 
advantages, a number of high-throughput small molecule screens have been performed 




such screens have been further developed and validated in other mammalian systems. 
Taken together, zebrafish models of human diseases clearly exhibit experimental 
strengths to understand disease pathogenesis and undertake therapeutic drug development 
for a wide range of human diseases.  
 
1.2.3 Zebrafish models of human liver cancer: Chemical carcinogenesis and 
transgenic approaches 
Chemical carcinogenesis, due to its technical simplicity and low cost, was the first 
approach used to demonstrate the spontaneous formation of benign and malignant tumors 
in zebrafish. Aqueous carcinogens can be dissolved or suspended directly in water and 
the zebrafish can be exposed for long periods of time. A number of chemical compounds 
that are carcinogenic in mammals were shown to induce tumor formation in zebrafish. 
Spitsbergen and Kent showed that exposure of zebrafish to structurally diverse 
carcinogens such as DMBA (7,12-dimethylbenz[α]anthracene) and MNNG (N-Methyl-
N'-Nitro-N-Nitrosoguanidine) could induce the formation of a significant number of 
neoplasms in various tissues with hepatic tumors as one of the most prominent lesions 
(Spitsbergen and Kent, 2003). Interestingly, these zebrafish cancers histologically 
resemble human tumors. In support of this, zebrafish possesses many orthologs of 
oncogenes and tumor suppressor genes found in mammals (Lieschke and Currie, 2007). 
Motivated by these findings, using cross-species comparative functional genomics 
approach, Lam and colleagues revealed the similarity of cancer gene signatures between 
human liver cancer and chemically-induced liver tumors in zebrafish, including genes 




Lam and Gong, 2006). Despite of the more than 300 million years of separation of the 
last common ancestor of fish and humans, this study provides molecular evidence that the 
biology of cancer is strikingly similar in these two phylogenetically distant species as 
well as the potential of using zebrafish in modeling human liver cancer. However, 
chemical carcinogenesis also displays disadvantages including low incidences of specific 
histological types of tumors, late tumor onset, spontaneous tumor growth under these 
conditions, and heterogeneity in genetic profile and location (Gong et al., 2010). With 
recent technological improvements, a predictable zebrafish tumor model can be easily 
established by transgenic approaches through the overexpression of a fused oncogene 
with fluorescent protein under control of a tissue-specific promoter. So far, several 
transgenic tumor models have been successfully generated using zebrafish to model 
human cancers. However, none of them have been generated to study liver cancer. In 
addition, human liver cancers, especially HCC, are a heterogeneous group of tumors that 
differ in risk factors and genetic alterations (Villanueva and Llovet, 2011). This strongly 
describes the need to establish a stable zebrafish liver cancer model driven by one or 
several oncogenes to accurately assess the functional aspects of specific molecular 
alterations during tumor development in the zebrafish, which may associate with 
corresponding tumorigenesis in humans.  
 
1.2.4 Application of conditional expression systems in transgenic zebrafish 
Tumor models developed in genetically tractable animals have gained unique insights 
into the molecular mechanisms underpinning human malignancy. Effective transgenesis 




zebrafish in modeling various cancer types. In the first example of transgenic cancer in 
zebrafish, the T-cell acute lymphoblastic leukemia (T-ALL) model was generated by 
Langenau and colleagues through expressing m-Myc oncogene under the T-cell-specific 
rag2 promoter (Langenau et al., 2003). The initiation, progression and invasion of T-ALL 
could be monitored via GFP fluorescence and all of these tumors were clonal. Exploiting 
the changes in fluorescent signal intensity as the leukemia spreads throughout the animal, 
this transgenic fish was utilized for chemical screens to identify compounds that suppress 
leukemogenesis (Trede et al., 2004). Enhanced by these pioneering works, a growing list 
of zebrafish tumor models has been established using a similar approach by introducing 
constitutive oncogenic expression in specific tissues. Although this method offered a 
rapid test for oncogenicity of the transgene in forming tumors and a simple way to obtain 
stable transgenic zebrafish, these models often developed severe cancers before the fish 
reached reproductive maturity, hindering maintenance of these transgenic lines. In 
addition, gene expression at earlier stages of development caused severe embryonic 
defects that obscure the roles of the transgene at later stages. Therefore, improved 
techniques that permit switching gene expression on and off would help to overcome 
these problems.  
Heat-shock inducible promoters have been well applied in embryos to study gene 
function during regeneration as well as homeostasis in adult fish (Liu and Leach, 2011). 
Although this method appears to work in all cell types, it lacks spatial control and allows 
low level expression of transgene. Another well-established method for conditional 
activation is the Cre/loxP system. In this strategy, Cre recombinase is a site-specific DNA 




Generally, a loxP-flanked STOP cassette or reporter gene was inserted between a 
promoter and a gene of interest to prevent transcription of the gene of interest. In the 
presence of Cre protein, excision of the DNA fragment between the two loxP sites results 
in expression of the gene of interest after recombination. Application of the Cre/loxP 
system was first adopted in zebrafish in 2005 (Langenau et al., 2005). Coupled with heat-
shock and/or tissue-specific promoters, Cre/loxP technology permits the location and 
timing of genetic manipulations to be closely regulated (Feng et al., 2007). A few years 
later, a chimeric CreERT2 recombinase has been generated to achieve a better temporal 
activation and improve the leakiness of Cre-mediated recombination (Hans et al., 2011). 
Alternatively, the yeast Gal4/UAS system, in which Gal4 can activate the expression of a 
gene placed downstream of UAS, was widely applied in zebrafish (Scheer and Campos-
Ortega, 1999). However, high level of Gal4 expression can be toxic, leading to 
developmental defects (Emelyanov and Parinov, 2008). In addition, the above 
technologies do not allow for reversible and reinducible expression. Another way to 
address these limitations is using the chemical-inducible systems, including inducible 
tetracycline (Tet)-on systems (Knopf et al., 2010) and mifepristone-inducible LexPR 
system (Emelyanov and Parinov, 2008). Emelyanov and Parinov demonstrated that one 
of the utilities of the mifepristone-inducible system is the generation of two independent 
driver and effector cassettes. The driver line carries a chimeric LexPR transactivator 
under the control of a tissue-specific promoter whereas the effector line harbors a gene of 
interest under the control of LexA binding sites. In double transgenic fish, transcription 
of the transgene is activated by the LexPR transactivator produced from the driver 




mifepristone removal. Collectively, these systems have succeeded in the temporal control 
of gene expression combined with the spatial control of tissue-specific promoters in 
developmental studies. Thus, with rapid improvement of transgenesis technologies, the 
zebrafish is firmly established as an effective model system for cancer research. 
 
1.3 Oncogenic Ras in human liver cancer 
1.3.1 Molecular perspective of Ras in cancer biology 
The Ras proto-oncogenes are central regulators of intracellular signal transduction 
pathways involved in malignant transformation and have long been at the leading edge of 
signal transduction and molecular oncology (Karnoub and Weinberg, 2008). There are 
three Ras gene isoforms in humans, namely HRAS, NRAS and KRAS. Activating somatic 
mutations in these genes, as well as mutations in the regulators and effectors of the Ras 
proteins, are prevalent in human cancer. Approximately 30% of all human cancers harbor 
an activating point mutation in Ras, with pancreas (60-90%), colon (35-50%), lung (20-
30%) having the highest frequency (Figure 1.3). These point mutations commonly cause 
amino acid substitutions at codons 12, 13 or 61, and G12V (glycine to valine) is more 
ubiquitously detected than the others in most types of human tumors (Schubbert et al., 
2007). Such mutational activation of Ras contributes to tumor formation, progression and 
metastasis in human malignancies. 
The interest in Ras started in the 1960s with the pioneering discovery of the 
Harvey and Kirsten rat sarcoma retroviruses, which were capable of isolating oncogenes 
from the host rat genome and were responsible for causing tumors in mice (Harvey, 




In 1982, the human homologs (named HRAS and KRAS) of these retroviral oncogenes 
were found and a year later, the third member of the Ras gene family was identified as a 
human transforming gene known as NRAS. HRAS, NRAS and KRAS have overlapping but 
distinct functions (Karnoub and Weinberg, 2008). Despite sharing high degree of 
sequence similarities, the frequency of mutations in the different Ras isoforms varies. In 
human tumors, majority of mutations occur in the KRAS gene (85%), followed by NRAS 
(15%) and HRAS (less than 1%) (Downward, 2003). 
Ras signaling is commonly hyperactivated in tumor cells and is capable of 
deregulating diverse downstream signaling pathways, leading to aberrant cell survival 
and proliferation (Schubbert et al., 2007). The Raf/MEK/ERK signaling pathway is the 
first Ras effector pathway to be characterized and the most widely studied thus far. 
Numerous evidences showed that the activation of MEK and ERK is required for Ras-
induced neoplastic transformation of murine cell lines (Downward, 2003). Indeed, 
activated ERK stimulates transcription factors, which can in turn activate the expression 
of several cell cycle regulatory proteins to drive proliferation. Apart from the 
Raf/MEK/ERK pathway, the phosphatidylinositol-3 kinase (PI3K) is another well-
characterized effector of Ras. Mutations in members of the PI3K pathway have been 
estimated to be found in up to 30% of human cancer (Luo et al., 2003). Activation of 
PI3K results in the downstream activation of AKT, which has emerged as a critical 
mediator for PI3K signaling in tumorigenesis due to its role in promoting cell survival 
(Shaw and Cantley, 2006). Both Raf/MEK/ERK and PI3K/AKT are interlinked signaling 
pathways that are crucial for growth and survival and have recently received enormous 





Figure 1.3 Distribution of KRAS somatic mutation frequency in human cancers. 
Barcharts showing the mutation frequency of KRAS in various human primary cancers of 
different tissues. Values (%) were obtained from Sanger Institute: Catalogue of Somatic 
Mutations in Cancer (COSMIC; http://www.sanger.ac.uk). Tissues with 0% mutation 




1.3.2 Association of Ras with HCC 
Although activation of Ras contributes to the pathogenesis and progression of many 
human malignancies, the exact mechanisms underlying Ras-driven liver tumorigenesis 
remain unclear. Approximately 7% of human liver cancer carries activating mutations in 
the KRAS oncogene, which is higher than the other two HRAS and NRAS isoforms 
(Karnoub and Weinberg, 2008). Earlier studies have shown that the core protein of 
hepatitis C virus was capable to directly activate the Ras-mediated Raf/MEK/ERK 
pathway in vitro (Hayashi et al., 2000). In later reports, increased expression levels of 
HRAS, NRAS and KRAS have been found in liver pre-neoplastic lesions and HCC in 
human (Coleman, 2003). The overexpression of Ras in nearly all examined cases of 
human HCC suggests that the Raf/MEK/ERK pathway is hyperactivated, when compared 
with its expression in normal livers and surrounding non-neoplastic liver tissues (Calvisi 
et al., 2006). It has also been found that there is high prevalence of KRAS mutations 
detected in approximately 42% of HCC cases in workers exposed to vinyl chloride 
(Weihrauch et al., 2001). Importantly, activation of the Raf/MEK/ERK and 
PI3K/AKT/mTOR pathways as major downstream effectors of Ras has been reported in 
most of human HCC cases (Downward, 2003; Schmidt et al., 1997; Calvisi et al., 2006; 
Newell et al., 2009). The involvement of Ras in human liver cancer is further supported 
by the approved use of Sorafenib (Nexavar®) in advanced HCC treatment (Villanueva 
and Llovet, 2011). Sorafenib is a multi-target compound which inhibits the 
Raf/MEK/ERK pathway and remains by far the only drug approved for the treatment of 
HCC. In recent years, several Ras-induced liver neoplasia in murine models have been 




directing the expression of mutant Hras to the liver (Sandgren et al., 1989). However, 
death occurred within several days of birth in majority of the transgenic mice born with 
enlarged livers. The remaining mice having lower levels of Hras only exhibited hepatic 
dysplasia but not HCC, and all ultimately died from development of lung tumors. Later, a 
second mouse model of HCC with β-catenin and Hras mutations simultaneously 
introduced by a liver-specific Cre expression system was generated (Harada et al., 2004). 
This model showed that mutations solely in Hras or β-catenin were insufficient to induce 
hepatocarcinogenesis, whereas a combination of both caused HCC. More recently, a 
chimeric mouse model of liver carcinoma transduced with HrasV12 retrovirus was created 
in which reactivation of p53 results in tumor clearance (Xue et al., 2007). Albeit this 
study indicated that p53 loss is required for the maintenance of aggressive carcinomas, 
mechanism of tumor progression in this model remained unreported. In addition, such 
tumor model is unfeasible for large-scale studies due to technical difficulties in 
generating sufficient number of chimeric animal. 
All the evidence indicates Ras as an attractive target for liver cancer therapy. 
However, there are still limited effective therapeutic strategies for HCC and the 
underlying mechanisms of liver tumorigenesis remain elusive. Further study of 
hepatocarcinogenesis by oncogenic Ras may help to identify critical molecular events for 
developing targeted therapies for human HCC, as well as provide additional insight into 
Ras signaling in general. To date, none of the genetically engineered mice has 
intentionally utilized Kras as a driving oncogene to study liver tumorigenesis. In addition, 
no global gene expression analyses were employed to evaluate how well these murine 




1.4 Objectives and significances of the study 
The main aim of this research project is to establish a liver cancer model through 
overexpression of oncogenic krasV12 in the liver of transgenic zebrafish to mimic human 
liver cancer. Several transgenesis techniques including constitutive and conditional 
(mifepristone-inducible LexPR and mifepristone-inducible Cre/loxP recombination) 
regulation of liver-specific EGFP-krasV12 expression were employed to generate 
predictable and high-incidence zebrafish liver cancer models. To achieve these 
objectives, three different sets of experiments were designed and performed. 
 Generation and analysis of constitutive liver-specific expression of oncogenic 
krasV12 in driving liver tumorigenesis in transgenic zebrafish.  
 Development and analysis of mifepristone-inducible and -reversible krasV12 liver 
tumorigenesis in transgenic zebrafish.  
 Development and analysis of mifepristone-inducible Cre recombination to 
conditionally control krasV12 liver tumorigenesis in transgenic zebrafish. 
When the stable EGFP-krasV12 transgenic zebrafish models of liver cancer have been 
firmly established, follow-up studies were then conducted to aim at several specific 
objectives as follows: 
 To examine the process of liver tumor development in EGFP-krasV12 transgenic 
zebrafish by fluorescence microscopy imaging and histopathological analysis.  
 To uncover the molecular mechanisms of krasV12-driven liver tumorigenesis by 
immunoblotting, immunohistochemical and microarray analyses. 
 To demonstrate alternative platforms for studying novel genetic mechanisms of 




Employing these models for liver cancer research should lead to greater insights into 
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2.1 General molecular biology techniques and plasmid construction 
2.1.1 Polymerase chain reaction (PCR) 
Standard PCR was performed in a total volume of 25 μl reaction mixture containing 2.5 
μl of 10× PCR buffer (Qiagen, Hilden, Germany, #1005479), 3 μl of 25 mM MgCl2 
(Qiagen, #1005482), 0.2 μl of 10 mM dNTP mix (10 mM each of dATP, dCTP, dGTP 
and dTTP; Qiagen, #201900), 0.5 μl each of forward and reverse primers (0.2 μg/μl), 1 U 
of Taq DNA Polymerase (250 U; Qiagen, #201203) and 100-500 ng of template DNA. 
Amplification was carried out in a PTC-100 Peltier thermal cycler (MJ Research, 
Hercules, CA). The cycling conditions were as follows: initialization at 95oC for 5 
minutes; 25-30 cycles of denaturation at 95oC for 30 seconds, annealing at 55-62oC for 1 
minute, extension at 72oC for 45-90 seconds; final extension at 72oC for 10 minutes. All 
PCR products were analyzed on 1% agarose gel (Bio-Rad Laboratories, Hercules, CA, 
#162-0133) stained with SYBR® Green (Sigma, #S9430) and visualized using an 
ultraviolet transilluminator in a gel documentation system (Bio-Rad Laboratories). 
 
2.1.2 Cloning 
Bacterial strains carrying plasmid of interest were incubated overnight at 37oC in 5 ml 
Luria-Bertani (LB) broth with antibiotic (200 mg/ml Ampicilin or Carbenicillin; Sigma). 
The Wizard® Plus SV Minipreps DNA Purification Systems (Promega, USA, #A1460) 
was used to isolate plasmid DNA from overnight culture following manufacturer’s 
protocols. Restriction enzymes purchased from New England Biolabs (Beverly, MA) 
were used to digest DNA for cloning or for identification of recombinant plasmids. All 
digestions were performed following manufacturer’s instructions. The digested DNA was 
analyzed by agarose gel electrophoresis and gel concentrations were 1-1.5% according to the 
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size of DNA of interest. Extraction of the desired DNA fragments from agarose gel was 
conducted using QIAquick Gel Extraction kit (Qiagen, #28706). DNA ligations were 
performed by incubating DNA fragment/insert with appropriately linearized cloning 
vector in the presence of buffer and T4 DNA ligase (New England Biolabs, #M0202S) at 
16oC overnight. The recombinant DNA plasmid was then transformed into DH5α 
Competent Cells (Invitrogene, #18265-017) according to manufacturer’s protocols. 
Subsequently, DH5α competent cells were recovered in 100 μl of LB at 37oC for at least 
2 hours (h) before spreading onto LB agar plates supplemented with an appropriate 
antibiotic. PCR and enzyme digestions were applied to screen and confirm the clone 
harboring the desired recombinant plasmid. The plates were incubated at 37oC overnight. 
Positive clones grown on LB agar plates with an appropriate antibiotic were cultured in 
LB broth with the same antibiotic for DNA extraction. Finally, the recombinant plasmid 
was extracted by mini-preps and purified prior to microinjection. 
 
2.1.3 Isolation of zebrafish kras oncogene and construction of Tg(fabp10:EGFP-
krasV12) plasmid 
A zebrafish krasB cDNA fragment was isolated by Dr. Emelyanov and Dr. Parinov using 
reverse transcription PCR with the two primers kras1: 5’-
GGAGCCAAGCGGCCGCATGACCGAATATAAGCTTGTG-3’ and kras2: 5’-
GGAAGGAAGCGGCCGCTCACATTAATGCACATTTTGTTTTG-3’ containing the 
NotI restriction endonuclease excised sequence (underlined). The primers were designed 
based on the zgc:85725 cDNA sequence (GenBank BC078646; GI:50925043) 
(Strausberg et al., 2002). The amplified product was digested with NotI and cloned into 
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the NotI site of the ET construct (Parinov et al., 2004) carrying a TAA stop codon after 
EGFP to terminate the translation of Kras. To produce the mutated (oncogenic) form of 
KrasV12 fused with EGFP, the TAA stop codon of EGFP cDNA was removed, and glycine 
in position 12 of Kras was replaced with valine using the QuikChange site-directed 
mutagenesis kit following manufacturer’s instructions (Stratagene, CA, USA, #200518) 
and primers Forward: 5’-
CTGTACAAGTTAAGCGGCGGCATGACCGAATATAAGCTTGTGGTCGTGGGAG
CTGTAGGCG-3’ and Reverse: 5’-
CGCCTACAGCTCCCACGACCACAAGCTTATATTCGGTCATGCCGCCGCTTAAC
TTGTACAG-3’. Alignment between human and zebrafish KrasV12 protein is shown in 
Figure 2.1. A 2.8 kilobase pair (kb) promoter of the fabp10 gene (Her et al., 2003) was 
digested and subcloned into the 0.6-kb miniDs construct pMDS6 (Emelyanov et al., 
2006) between the NotI and SacII sites. The produced construct was then inserted with 
the fused EGFP-krasV12 sequence between the NotI and SacII sites. As a result, the 
product transcribed from the fabp10 promoter is a fusion protein of EGFP and KrasV12.  




Figure 2.1 Alignment of human and zebrafish KrasV12 amino acid sequences. 
Human: KRAS2B: GenBank accession NP_004976.2; GI:15718761. Zebrafish: 
Zgc:85725 GenBank accession NP_001003744.1; GI:51230609 encoded by zgc:85725 
mRNA (cDNA clone MGC:85725 IMAGE:6968999) GenBank accession BC078646; 
GI:50925043 (Strausberg et al., 2002). Identical amino acids are highlighted in black, 
different amino acids in gray and mutated glycine to valine are not highlighted. 
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2.1.4 Construction of inducible transgenic systems 
The liver driver/reporter construct was made by replacing krt4 promoter of the 
pDs(krt4:LPR-LOP:G4) (Emelyanov and Parinov, 2008) with the fapb10 promoter 
through the XhoI/AscI sites. The Kras effector construct was generated by inserting the 
amplified krasV12 mutant digested with NotI and SacII enzymes (Nguyen et al., 2011) into 
the same sites of the pDs(cry:C-LOP:Ch) vector (Emelyanov and Parinov, 2008) 
containing a selection marker, mCherry, which is driven by the zebrafish crybB 
(crystallin beta B) promoter to give a red fluorescence in the lens. The NLS-Cre 
containing a nuclear localization sequence (NLS) was amplified by Dr. Emelyanov 
(Temasek Lifescience Laboratory, Singapore) by PCR from the pACN (Bunting et al., 
1999) using primers 5’-
AGAGGAATTCCACCATGGCCAATTTACTGACCGTACACAAAATTTGC-3’  and 
5’-CCTGCTGGAAGATGGCGATTAGCCATTAA-3’. The product was used as a 
template in the secondary PCR using primers 5’-
AGAGGAATTCCACCATGGCACCCAAGAAGAAGAGGAAGGTGGCCAATTTAC
TGACCGTACACAAAATTTGC-3’ and 5’- 
CCTGCTGGAAGATGGCGATTAGCCATTAAGCTTATAGCGGCCGCAGAG-3’. 
The product, which contained a nuclear localization sequence (bold) fused to Cre 
recombinase and Kozak sequence (italic) was digested with EcoRI/NotI (underlined) and 
cloned into the same sites of the pDs(cry:C-LOP:Ch) vector (Emelyanov and Parinov, 
2008) to obtain the Cre effector construct. The LChL-Ras contruct was generated by 
cloning the fabp10 promoter cut at XhoI/PmeI sites into pMDS6 vector (Emelyanov et 
al., 2006) containing loxed mCherry-STOP cassettes with lox2272 sites for Cre 
recombinase in front of the fused EGFP-krasV12 sequences.  
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2.2 Generation of transgenic zebrafish 
2.2.1 Zebrafish maintenance 
Zebrafish were maintained according to established protocols (Westerfield, 2000) at the 
Temasek Life Sciences Laboratory fish facility in a controlled environment with a 
photoperiod cycle set at 14 hours of light and 10 hours of dark. Zebrafish embryos were 
raised in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4 and 
0.0001% methylene blue) in a 28oC incubator until 4-5 days post-fertilization (dpf) 
before transferring to an aquatic housing system. In addition, embryos between 10-28 
hours post-fertilization were bleached using 0.004% NaOCl in E3 medium for exactly 5 
minutes to prevent any bacteria, fungus and parasite contamination. In order to maintain 
the growth and fecundity of adult zebrafish, they were fed with flake foods (Aquori, USA) 
and Artemia nauplii (World Aquafeeds, USA), and kept under the photoperiod cycle set at 14 
hours of day (light) and 10 hours for night (dark). In the afternoon of the day before embryo 
collection, pairs of male and female fish were placed into a mating tank with an inner sieved 
container and separated by a spacer. The next morning, embryos were collected from the 
bottom of the mating tank after placing the paired fish together for breeding by removing the 
spacer. All experiments involving animals were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the National University of Singapore. 
 
2.2.2 RNA synthesis, microinjection and screening of transgenic fish 
The TPase plasmids (Emelyanov et al., 2006) were linearized downstream of the poly(A) 
tail with the BamHI restriction enzyme and used for generating capped Ac mRNA in vitro  
with the mMESSAGE mMACHINE® SP6 kit (Ambion, Austin, Texas, #AM1340) 
following manufacturer’s manual. The products were purified using the RNeasy mini kit 
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(Qiagen, Hilden, Germany, #74104). A total of 5-10 pg of plasmid DNA was co-injected 
with 25-50 pg of synthesized transposase mRNA into zebrafish embryos (yolk center) at 
the one- to two-cell stage. Injected embryos were kept and maintained according to 
established protocols (Westerfield, 2000). 
All of the surviving embryos after injection were kept until adult stage. For 
transgenic screening, the founder zebrafish were mated with wild-type (WT) to obtain F1 
generation. The F1 progeny was examined using Nikon SMZ1600 fluorescent 
stereomicroscope (Nikon Instruments) for the presence of fluorescent marker indicating 
the integration of specific transgene into fish genome. Only the lines that segregated as a 
single locus (produced 1:1 ratio when out-crossed to non-transgenic fish) were selected. 
Although copy number of transgenes in each line was not determined, only the lines that 
segregated as a single locus were used. These lines may contain several closely linked 
copies of the constructs; however, it does not complicate line maintenance or expression 
analysis. 
 
2.3 Gross morphological and histopathological analyses of zebrafish tumor 
Zebrafish were anaesthetized in 0.1% 2-phenoxyethanol (Sigma, #P1126), dissected to 
expose the abdominal area and examined under the Nikon SMZ1600 stereomicroscope 
(Nikon Instruments) for liver gross morphology. The liver of each fish was diagnosed 
based on the color, size and shape, and any presence of visible liver tumor(s). If tumors 
were present, one-third or half of each tumor was retained and stored at -80oC for 
additional assays. Brightfield and fluorescent images were taken using Nikon 
DXM1200F digital camera with MetaVue bioimaging software (Molecular Devices, 
Materials and Methods 
32 
 
Sunnyvale, CA). Fish were then fixed in either Bouin’s solution (Sigma, #HT10132) or 
10% neutral buffered formalin solution (Sigma, #HT5012) for 5 days, dehydrated 
through a series of graded ethanol solutions (70% ethanol for 1 hour; 90% ethanol for 2 
hours; 95% ethanol for 1 hour; 100% ethanol for 2 hours; twice in 100% ethanol for 1 
hour), washed in clearing agent (Histo-Clear®; Fisher Scientific, Pittsburgh, PA, #HIS-
010-010S) and embedded into paraffin blocks. Cross or sagittal sections of 4-6 μm 
thickness were made from the embedded samples using a Leica cryostat microtome 
(Cambridge, United Kingdom) and placed onto charged Superfrost Plus microscope 
slides (Fisher Scientific, #12-550-15). The sections were deparaffinized in Histo-Clear®, 
rehydrated in a series of graded ethanol solutions (100% ethanol for 3 minutes; 90% 
ethanol for 3 minutes; 70% ethanol for 3 minutes; 50% ethanol for 3 minutes; twice in 
deionized water for 5 minutes) and routinely stained with hematoxylin and eosin (H&E). 
The following steps were carried out in H&E staining: hematoxylin (Sigma, #51275) for 
30 minutes; deionized water for 1 minute; acid alcohol (1% HCl in absolute ethanol) for 
5-10 seconds; deionized water for 1 minute; running tap water for 3-4 minutes; deionized 
water for 1 minute; 50% ethanol for 3 minutes; 70% ethanol for 3 minutes; 90% ethanol 
for 3 minutes; eosin (Sigma, #HT110232) for 3 minutes; 90% ethanol for 3 minutes; 
twice in 100% ethanol for 3 minutes; Histo-Clear® for 5 minutes. Stained slides were 
then mounted in DePeX mounting medium (BDH Laboratory Suppliers, Poole, United 
Kingdom, #361252B). 
Slides were diagnosed by Dr. Jan Spitsbergen (Oregon State University, 
Corvallis, OR) to define specific liver lesions. Zebrafish liver tumors were graded based 
on the criteria developed for classifying rodent liver neoplasms and foci of hepatocellular 
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alterations. The most anaplastic zebrafish tumors would have prominent nucleoli, 
hyperchromatism and the greatest nuclear irregularity. 
 
2.4 Tumor screening for the inducible systems 
Each group of induced krasV12 transgenic zebrafish was screened under the fluorescent 
Nikon SMZ1600 stereomicroscope every week to determine the rate of tumor induction. 
Liver tumor in induced transgenic zebrafish was defined as EGFP-labeled cells widely 
occupying at least half of its liver (for mifepristone-inducible Cre/loxP system) which 
also grew to at least twice the size of normal liver in driver transgenics (for mifepristone-
inducible Cre/loxP and mifepristone-inducible systems). All the tumor-bearing fish were 
dissected to expose the abdominal area and pictured by the Nikon DXM1200F digital 
camera. Fish were then fixed in Bouin’s fixative, embedded in paraffin, sagittal 
sectioned, and stained routinely with H&E preceding histopathological diagnosis to 
confirm the liver lesion. 
 
2.5 Transplantation of liver tumors into wild-type zebrafish 
Adult AB strain WT zebrafish were gamma-irradiated with 25 Grays and recovered for 2 
days before transplantation. Liver tumors were aseptically dissected from 1-year-old 
EGFP-krasV12 transgenic donors, washed twice with PBS and gently minced into small 
pieces prior to homogenization. Tumor cells were resuspended in Hanks’ balanced salt 
solution (HBSS; Gibco®, Grand Island, NY, #14025-092) to a concentration of 1 × 106 
cells per 10 μl. Ten μl of cell suspension were injected intraperitoneally using a 25-μl 
Hamilton syringe (Hamilton Company, Bonaduz, Switzerland) into the left-side of 
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immobilized previously irradiated recipients. Mock recipients were injected with 10 μl of 
HBSS as control. After transplantation, fish were kept overnight in dechlorinated tap 
water containing 0.01% methylene blue (Sigma, #M9140). Transplanted fish were 
monitored weekly for the presence of EGFP fluorescence using Nikon SMZ1600 
stereomicroscope (Nikon Instruments). 
 
2.6 Isolation of total RNA/genomic DNA and PCR 
2.6.1 Isolation of total mRNA 
Liver tissues or tumors were sampled from WT or transgenic zebrafish and snap-frozen 
in liquid nitrogen. Total RNA was isolated using TriZOL reagent (Invitrogen, #15596-
018) following manufacturer’s instructions and resuspended in diethyl pyrocarbonate 
(DEPC; Sigma, #D5758) water. RNA concentrations were measured using NanoDrop™ 
3300 (Thermo Scientific, Wilmington, DE). One unit of A260 is equivalent to 40 μg/ml of 
RNA. Integrity of all RNA samples was evaluated by UV spectrophotometry and agarose 
gel electrophoresis. A260/A280 ratio of 1.8-2.0 indicates high quality RNA. 
 
2.6.2 Reverse transcriptase PCR 
One μg  of total  RNA was used  as a  template to  synthesize  cDNA in a  25 μl  RT-PCR 
reaction mixture containing 5 μl of 5×RT-PCR buffer, 1 μl of dNTPs mix (containing 10 
mM of each dNTP), forward primer 0.3 μM (final concentration), reverse primer 0.3 μM 
(final concentration) and 1 μl of one-step RT-PCR enzyme mix using the One-Step RT-
PCR Kit (Qiagen, #210212). Amplification was carried out in a PTC-100 Peltier thermal 
cycler (MJ Research). The RT-PCR conditions were: reverse transcription at 50oC for 30 
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minutes; initial PCR activation at 95oC for 15 minutes; 35 cycles of 94oC for 30 seconds, 
55oC for 10 seconds and 72oC for 10 seconds; final extension at 72oC for 10 minutes. The 
reaction mix was kept on ice till the thermal cycler reached 50ºC, and then placed in the 
thermal cycler and carried on with the RT-PCR reaction. Primers used in the one-step 





CATTGTGAGGAGGGCAAAGT-3’. All PCR products were analyzed on 1% agarose 
gel (Bio-Rad Laboratories) stained with SYBR® Green (Sigma) and visualized using an 
ultraviolet transilluminator in a gel documentation system (Bio-Rad Laboratories).  
 
2.6.3 Quantitative real-time PCR 
One μg of total RNA was reverse transcribed to cDNA using the SuperScript® II cDNA 
Synthesis Kit (Invitrogen, #11917-020) following manufacturer’s instructions. After 
cDNA synthesis, the samples were diluted with nuclease-free water to a volume of 100 
μl. Quantitative real-time PCR was performed in a 25 μl reaction volume containing 0.5 
μl each of forward and reverse primers (10 μM), 1 μl of cDNA as the template and the 
iQ™ SYBR Green Supermix (Bio-Rad Laboratories, #170-8880) with an iQ™ single-
color real-time PCR detection system (Bio-Rad Laboratories). Optimal primer annealing 
temperatures varied with each primer pair and optimal amplification was generally 
completed in 40 cycles. Basically, one cycle includes denaturation at 95°C, annealing at 
58-62°C (variable), and extension at 72°C, followed by a melting curve analysis as described 
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in the manufacturer’s protocol. Reactions were run in triplicates for each sample. Gene 
expression levels in each WT/transgenic liver sample were normalized with the 
expression level of β-actin as the internal control. The log2 fold-changes in expression in 
the transgenic sample as compared to the WT sample were then calculated using the CT 
method (Schmittgen and Livak, 2008) following the formula: log2 fold-change = -∆∆CT 
= -[(CT gene of interest - CT β-actin)transgenic sample - (CT gene of interest - CT β-
actin)WT sample]. For quantification of endogenous kras and transgenic krasV12 
transcript levels, the log2 fold-changes in expression were calculated using the formula: 
log2 fold-change = -∆CT = -[(CT gene of interest - CT β-actin)transgenic sample] 
(Schmittgen and Livak, 2008). Primer sequences used for amplification in quantitative 
real-time PCR are listed in Table 2.1. 
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Table 2.1 Primer sequences used in quantitative real-time PCR 
Gene Forward primer (5’ → 3’) Reverse primer (5’ → 3’) 
β-actin CCACCTTAAATGGCCTAGCA CATTGTGAGGAGGGCAAAGT 




krasV12 CGACCACTACCAGCAGAACA GCTTTTGCCTACGCCTACAG 
map2k1 AAAGAGCAGACCTCAAGCAG TTCAGGAGGCAGTAGTTTGC 
map2k2 TGCCTCATAAAGAACCCTGC AGGCTTACAAGCATACAGGC 
map4k2l TGATCTGGAGGACAAGGACC AGAAAGAGCTGCGTCTCTGC 
map4k5 AGGACAGTGTTCTGGCATTC ATACAAAGGCTCCAGCAGTG 
mapk1 GGATGATTTGCCCAAAGAGA GTCAGGTGAACGTTGAGGGT 
mapk3 GAGTCGGTGAAGGGACAAAA TGATCCCGATGATGTTCTCA 
mapk8 CTGCTGCAGATGACCATCCTTT ACAGAGCATATTTGAGGGGGCT 
mapk12 GTGAAATGACGGGCTACGTT AGACTGTAGCTTCGCTGTGA 
mapk14a CCCGTGCAGTATCAGAACTT CAGACTTGTGGCAGGTGTAA 
mapkapk5 GACACAAGAACGATTTGCCC CTGGCTGATTCTGTGGAACA 
mdm2 AACTCCCAACACAACCTTCG GGGTCTCTTCCTGACTGCTG 
nfya CGCGCCAAACTGGAGGCTGA TTTACCCCAGAGGCGGGGCA 
nlk1 GTGCCAAGTCCTGCTGAAAT AGTCGATTTGTGGAGGTTGG 
raf1 ATGCCATACGTGTTCACAGC TCCCTTTGTGTACGGTTCCA 
rpl19 CTTGCGCTGTGGCAAGAAGAA TTCTCGGGCATACGTGCGTT 
stat3 CTGAAACCTTGAGCGACACA AGCAGGTTGTGGAAGACCAG 
stmn1 CTCTGAAGGGCATACTTGGACC CTGCTTCATGAGACTTGCGTCTC 
tgfb1 ATGATAGAATGGCTGCAGGG TGCAAGAGAGTTGCCATTTG 
tp53 GATGGTGAAGGACGAAGGAA ACAAAGGTCCCAGTGGAGTG 
zgc:194152 CTTCCTCTACCCGCATCGTCC AACTGGCACTGCTTTCACGC 
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2.6.4 Isolation of genomic DNA and genotyping PCR 
Adult zebrafish to be genotyped were anesthetized using system water containing 
Tricaine (80 µg/mL final concentration) to collect the tail fin using surgical razor blades. 
After fin clipping, each fish was individually kept in recovery tank containing system 
water with methylene blue. Genomic DNA was extracted using the DNeasy Blood & 
Tissue Kit (Qiagen, # 69504) according to manufacturer’s protocols. PCR was then 
performed using gene specific primers with a standard PCR program. The primers used 
for genotyping PCR are listed in Table 2.2. All PCR products were analyzed on 1% 
agarose gel containing SYBR® Green and visualized using an ultraviolet transilluminator 
in a gel documentation system. 
 
Table 2.2 Primer sequences used in genotyping PCR 
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2.7 Western blot analysis 
Total proteins were isolated from samples using lysis buffer (10 mM Tris-HCl pH 7.4 
and 1% SDS) containing protease inhibitors (Complete™ Mini; Roche Diagnostics, 
Mannheim, Germany, #1836153). Protein concentrations were determined using the 
Bradford dye (Bio-Rad Laboratories, #500-0006) following manufacturer’s instructions. 
Twenty μg of total proteins were mixed with equal volume of 2× Laemmli sample buffer 
(Bio-Rad Laboratories, #161-0737), boiled for 5 minutes and separated in a 10% gel by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were 
then transferred onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad 
Laboratories, #162-0177) at 100 V for 1 hour. Non-specific sites were blocked with 
SuperBlock® blocking buffer (Pierce Biotechnology, Rockford, IL, #37537) for 1 hour. 
The blot was incubated in the primary antibody overnight at 4oC, followed by the 
appropriate anti-mouse (#62-6520) or anti-rabbit (#65-6120) IgG conjugated with 
horseradish peroxidase (HRP) were from Invitrogen (Carlsbad, CA) for 1 hour. Signals 
were detected using SuperSignal® West Femto chemiluminescent substrate (Pierce 
Biotechnology, #34095) and exposure to X-ray film (Pierce Biotechnology, #34090). 
Primary antibodies used for immunoblotting are as follows: K-Ras F234 (#sc-30), 
K-Ras-2B C-19 (#sc-521) and p21 Waf1/Cip1 (#sc-2946) were from Santa Cruz 
Biotechnology (Santa Cruz, CA); Phospho-p44/42 MAPK (Thr202/Tyr204; #9101), 
Phospho-MEK1/2 (Ser217/221; #9121), Phospho-AKT (Ser473; #3787); Phospho-S6 
(Ser235/236; #2211) p53 (#9282) and Phospho-MDM2 (Ser166; #3521) were from Cell 
Signaling Technology (Beverly, MA); β-actin (#A1978) were from Sigma. Cre was from 
Novagen (Madison, WI; #69050). Goat anti-rabbit (#65-6120) and anti-mouse (#62-
6520) IgG conjugated with horseradish peroxidase (HRP) were from Invitrogen 
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(Carlsbad, CA). All primary antibodies were used at a working dilution of 1:1000 
whereas dilution of 1:10000 was applied for secondary antibodies.  
 
2.8 Immunohistochemistry 
Immunohistochemical analysis was performed on 5 μm sections of formalin-fixed and 
paraffin-embedded tissues. Sections were first boiled for antigen retrieval in 10 mM 
citrate buffer pH 6.0 or 9.0 (Abcam, #ab64214) for 10 minutes, treated with 3% hydrogen 
peroxide (Sigma, #H1009) for 10 minutes and blocked using SuperBlock® Blocking 
Buffer (Pierce Biotechnology, #37515) for 30 minutes. Sections were then incubated with 
the primary antibody in a humidified chamber at 4oC overnight. Primary antibodies used 
for immunohistochemistry in this study as following: Phospho-p44/42 MAPK 
(Thr202/Tyr204), Phospho-MEK1/2 (Ser217/221), Phospho-AKT (Ser473) were from 
Cell Signaling Technology; β-catenin (#ab32572), E-cadherin (#ab1416) were from 
Abcam (Cambridge, United Kingdom); and Ki67 (#P6834) was from Sigma. After 
washing 4× with PBS for 30 minutes each, sections were incubated in the appropriate 
secondary antibody for 1 hour at room temperature. Signals indicating peroxidase activity 
were visualized using the Metal Enhanced DAB substrate kit (Pierce Biotechnology, 
#34065) or Liquid DAB & Substrate Chromogen system (DAKO, Denmark, #346811) 
following manufacturer’s instructions. The sections were then counterstained with 
hematoxylin (Sigma, #51275), dehydrated and permanently mounted for microscopic 
examination. 
 
2.9 Cellular senescence and cell death analyses 
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Cryostat sections of liver tissues from WT or transgenic zebrafish were prepared by first 
fixing the tissues in cold 4% paraformaldehyde (PFA; Sigma, #P6148) for 1 hour at room 
temperature and then overnight at 4oC. After fixation, tissues were washed several times 
with PBS before incubating in 30% sucrose (Sigma, #S0389) at 4oC overnight. Tissues 
were embedded and frozen at -20oC for at least 30 minutes, and the embedded samples 
were then sectioned into 5-10 μm thickness using a Leica cryostat microtome. Sections 
were placed on Superfrost Plus microscope slides (Fisher Scientific), dried at 46oC for 2 
hours and either stored at -80oC or continued with the staining assay. As senescence-
associated β-galactosidase activity is a widely used biomarker for assessing cellular 
senescence, senescence-associated β-galactosidase expression was detected in cryostat 
sections using the staining kit supplied by Cell Signaling Technology (#9860) according 
to manufacturer’s instructions. On the other hand, the single- and double-stranded DNA 
breaks that occur at the early stages in apoptotic cells in liver tissues were stained using 
the In Situ Cell Death Detection Kit according to the manufacturer's protocol (Roche 
Diagnostics, #11684817001). Sections might be counterstained with hematoxylin prior 
microscope analysis using Axioplan2 inverted microscope (Carl Zeiss MicroImaging, 
Thornwood, NY). 
 
2.10 Zebrafish oligonucleotide microarray construction and hybridization 
The oligonucleotide probes for this array were designed by Compugen (San Jose, CA) 
and synthesized by Sigma Genesis (Saint Louis, MO). Each array contained 23,232 
zebrafish oligonucleotide probes, in which 15,559 probes were annotated with human 
homologues including 186 spots representing the same β-actin probe as internal controls. 
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The arrays were spotted using a custom-built DNA microarrayer at the Genome Institute 
of Singapore (GIS) and post-processed according to quality-controlled standard 
procedures. Hybridization procedures were carried out according to the well-established 
protocol of GIS (Lam et al., 2009a, 2009b) and done by Dr. Vivien Koh. For fluorescence 
labeling of cDNA, 10 µg of total RNA each from the experimental and reference RNA 
samples were first reverse-transcribed in the presence of dNTPs (Invitrogen, #10297-018) 
mixed with aminoallyl-labeled dUTPs (Sigma, #A0410), followed by coupling with 
mono-functional NHS-ester Cy3 (GE Healthcare, Buckinghamshire, United Kingdom, 
#PA13101) and Cy5 (GE Healthcare, #PA15101) dyes. Samples from WT or transgenic 
livers were labeled with Cy5 while reference samples pooled in equal amounts from 
whole WT male and female adult zebrafish were labeled with Cy3. For each array, the 
Cy5-labeled cDNA from the experimental sample was combined with the Cy3-labeled 
cDNA from the reference sample, concentrated and then resuspended in DIG Easy Hyb 
buffer (Roche Diagnostics, #11603558001) for hybridization at 42°C for 16 hours in a 
MAUI™ hybridization chamber (BioMicro Systems, Salt Lake City, UT). The arrays 
were distributed as follows: hyperplastic livers (age 3 months) and carcinomas (age 9 
months) from transgenic zebrafish, as well as normal livers from age-matched WT 
zebrafish. A minimum of two independent replicate hybridizations were performed from 
at least five biological replicates. After hybridization, the arrays were washed in a series 
of washing buffers, dried using low-speed centrifugation and scanned for fluorescence 
detection using the GenePix 4000B Axon scanner (Molecular Devices). 
 
2.11 Transcriptomic analyses 
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In this project, GSEA (Gene Set Enrichment Analysis) (version 2.0.1; Broad Institute) 
was first used to investigate how the physiological pathways and processes of 
hyperplastic liver might differ from liver carcinoma over the course of liver 
tumorigenesis in krasV12 transgenic zebrafish. Two collections of pre-defined gene sets 
compiled from the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) databases used in the GSEA analysis were retrieved from the Molecular 
Signature Database (MSigDB v2.5). In another approach, cross-species analysis by 
GSEA was utilized to further assess whether krasV12 zebrafish liver tumors are similar to 
human HCC or other cancer phenotypes, as well as to identify if any conserved gene 
signature involved in driving tumorigenesis exists between zebrafish and human cancer. 
Zebrafish up- and down-regulated enriched genes representing a particular stage of 
krasV12 liver tumorigenesis were hence identified for these comparisons. GSEA was 
performed using 1000 permutations with a weighted statistic to calculate the enrichment 
results. The enrichment score (ES) for each gene set was then normalized across analyzed 
gene sets to yield the normalized enrichment score (NES). The ES is defined as a 
measurement of the degree to which a particular gene set S is overrepresented at the 
extremes of the whole ranked gene list L. Thus, if the genes in S are preferentially found 
at the top of L, the ES(S) value will be high indicating up-regulation of S. The 
significance level and adjustment for multiple hypothesis testing were performed by 
permutation-based procedures (Subramanian et al., 2005). The nominal (NOM) p-value 
and false discovery rate (FDR) q-value were respectively used to estimate the statistical 
significance of the ES and maintain the number of expected false-positive findings below 
a statistical threshold. In the case of cross-species multiple data sets comparison, the FDR 
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q-value and family-wise error rate (FWER) p-value were used as the statistical controls. 
Additional information of the workflow for microarray data analysis is described and 
illustrated in Chapter 2, Section 3.1. 
 
2.12 Inhibitor treatment 
Driver/Ras-effector larvae were arrayed in 96-well plate at a density of two per well in 
which 200 μL E3 embryo medium (Westerfield, 2000) containing 1 μM mifepristone 
(Sigma) was added with one of the following assigned inhibitor(s):  10 μM PD98059 
(Calbiochem); 10 μM LY294002 (Sigma); 0.7 μM Rapamycin (Calbiochem); 10 μM 
PD98059 + 10 μM LY294002; or 10 μM PD98059 + 0.7 μM Rapamycin. Each treatment 
group contained 100 larvae and was repeated at least twice independently. Concentration 
of drugs was proposed based on data from a preliminary screening for developmental 
toxicity (Emelyanov and Parinov, unpublished data). The treatments were initiated from 
3 dpf and continued until 7 dpf, except for treatments with Rapamycin which were started 
at 3.5 dpf to avoid its adverse effects on normal development (Makky et al., 2007). In 
parallel, Driver/Ras-effector and driver larvae used as control were induced with 1 μM 
mifepristone and incubated with only 0.01% DMSO (dimethylsulphoxide). All were 
maintained in the dark at 28°C. Drug effects were assessed after 72 hours post-treatment. 
To evaluate inhibitor efficacy, liver size of treated larvae was classified into three 
categories as “normal” liver (full recovery of liver size comparable to normal liver in 
driver transgenics), “huge” liver (the liver remained hyperplastic) and “large” liver (a 
lesser regression in size which is still larger than normal liver but smaller than 
hyperplasia). 
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2.13 Statistical analyses 
Kaplan-Meier curves were computed using the survival distribution of each test group. 
The log-rank test was used to compare significant differences in death rates between 
different groups of transgenic fish constitutively expressing krasV12 in the liver with non-
trangenic siblings as control. In addition, the Kaplan-Meier analysis was also used to 
compare tumor induction rate, tumor incidence and identify tumor latency among groups 
of induced transgenic zebrafish with uninduced transgenics of the mifepristone-inducible 
or mifepristone-inducible Cre/loxP recombination systems. A p < 0.01 was chosen to be 
statistically significant. On the other hand, statistical analysis was performed by a 
Student’s t-test for direct comparisons between control and studied groups. Based on 
















3.1 Constitutively high level of liver-specific expression of oncogenic krasV12 
drives liver tumorigenesis in transgenic zebrafish 
3.1.1  Generation of Tg(fabp10:EGFP-krasV12) transgenic zebrafish 
A plasmid construct was made to harbor a cDNA encoding a fusion protein of N-terminal 
enhanced green fluorescent protein (EGFP) and C-terminal zebrafish KrasV12 under 
control of the liver-specific fabp10 promoter (Figure 3.1A). The construct also contained 
Ds transposon sequences (Emelyanov et al., 2006) and was co-injected with synthesized 
Ac transposase mRNA into one-cell embryos. One month later, 25% of F0 fish with 
EGFP fluorescence in the liver showed enlarged abdomen, edema and died within 2 
months. In contrast, siblings with no observable EGFP expression in the liver appeared 
normal and could carry the transgene insertions in germ cells. To obtain stable transgenic 
line, these normal F0fish were crossed with WT zebrafish and their offspring were 
screened for EGFP expression in the liver. Two founders transmitted the transgene to 
their progenies (F1). 
In F1 generation of the two founders (F1/I and F1/II), EGFP expression could be 
detected from 3 dpf (Figure 3.1B). Higher intensity of EGFP fluorescence was observed 
in F1/I than in F1/II. As compared to fabp10-dsRed  transgenics as control fish showing 
normal liver morphology (Figure 3.1C, D), microscopic examination of the EGFP-
positive F1/I (n = 196) at 7 dpf revealed that the majority of transgenic larvae had 
different degrees of liver enlargement (Figure 3.1E, F), whereas 7% exhibited small liver 
(Figure 3.1G). In F1/II (n = 149), 63% of larvae showed an enlarged liver and 3% had 
impaired liver, while 34% showed no significant abnormalities that correlated with lower 




abdominal swelling and progressive hemorrhages surrounding the abdominal walls 
(Figure 3.1I, J). Fish with impaired livers worsen with time and most died by 1 month 
post-fertilization (mpf) (Figure 3.1K). The effect of oncogenic krasV12 on liver 






Figure 3.1 Generation and characterization of Tg(fabp10:EGFP-krasV12) transgenic 
zebrafish. (A) Schematic diagram of the DNA construct used for generation of 
Tg(fabp10:EGFP-krasV12) transgenic zebrafish. Ds, maize Ds transposon sequence. (B-
G) Liver specific expression of EGFP-KrasV12 in F1 transgenic fry (B, E, F, G) as 
compared to Tg(fabp10:dsRFP; elaA:EGFP) transgenic line expressing RFP in liver 
(Korzh et al., 2008) as normal control (C, D). Stages are indicated as dpf (day post-
fertilization). (H-K) Gross observation of control fish (H) and F1 krasV12 transgenic fish 







Figure 3.2 Morphological development of liver in transgenic fish expressing EGFP-
krasV12. (A-D) Normal liver morphogenesis in LiPan Tg(fabp10:dsRFP; elaA:EGFP) 
zebrafish (Korzh et al., 2008) as control. (E-L) Two representative cases of abnormal 
liver morphogenesis distinguished by different degrees of liver enlargement/hyperplasia 
observed in the F1/I Tg(fabp10:EGFP-krasV12) zebrafish. Note that there were no obvious 
differences between these two cases at the later stages. (A, E, I) 7 dpf (days post-
fertilization); (B, F, J) 15 dpf; (C, G, K) 30 dpf; (D, H, L) 90 dpf. All large images are 





3.1.2  High level of krasV12 expression led to early lethality and induced HCC 
The Kaplan-Meier survival curves for heterozygous F1 offspring (n = 262, F1/I; n = 311, 
F1/II) showed approximately 70% mortality by 30 dpf (Figure 3.3A). Most of the fish 
which died before 30 dpf showed severe liver enlargement. By 90 days, 100% mortality 
was observed in F1/I. In contrast, 24% of F1/II transgenic fish survived by 90 dpf, thus 
enabling the maintenance of this line. Fish that survived past 90 days exhibited lower 
EGFP level in the liver. F2/II (n = 356), which was obtained by outcrossing, showed 
Mendelian 1:1 EGFP segregation, indicating a single transgene insertion.  
 Figure 3.4A-C shows normal liver morphology and histology in WT zebrafish. 
Approximately 58% of F1/I transgenics (n = 12), which died at 65-90 dpf, showed 
macroscopic liver nodules. Detailed histological progression of liver tumors was 
conducted with the F2 generation of line II. No tumor protrusion was found in the livers 
of 45 transgenic fish displaying swollen belly euthanized at 3 mpf (Figure 3.4D). 
However, 16 fish (36%) displayed moderate liver hyperplasia (Figure 3.4E, F). At the 
later stages, liver tumors in 12/54 (22%) F2/II fish dissected at 6 mpf were observed, 
showing histopathological features of hepatocellular adenoma (Figure 3.4G, H, I). By 9 
mpf, malignant HCC appeared in 11/42 (26%) transgenics (Figure 3.4J, K, L). These fish 
showed hemorrhage and swollen body upon death, with 5 of them showing invasions of 
tumor cells into blood vessels and internal organs (Figure 3.4M, N, O).  
Next, quantitative real-time PCR (qRT-PCR) was employed to assess the levels of 
endogenous and transgenic kras transcripts in the transgenic livers. Samples were 
collected from six groups: 3 mpf F1/I (carcinoma), 3 mpf F1/II (hyperplasia), 3 mpf N-
F2/II (normal liver), 3 mpf H-F2/II (hyperplasia), 9 mpf C-F2/II (normal liver) and 9 mpf 




levels of endogenous kras were consistent among these six groups, which were at similar 
levels as in age-matched WT controls. In contrast, transgenic krasV12 was overexpressed 
in these groups. F1/I had the highest level of krasV12 expression with log2 fold change 
over β-actin (9.85 ± 2.69) as compared to that in F1/II (6.95 ± 2.24). In F2/II, the levels of 
krasV12 transcript in transgenic fish undergoing tumorigenesis from hyperplasia (6.58 ± 
1.81) to carcinoma (7.60 ± 1.21) were higher than their age-matched transgenic siblings 
without liver lesions (3.26 ± 0.65 and 2.12 ± 1.88, respectively). These data demonstrated 
the threshold level of krasV12 to drive liver tumorigenesis as only high level of krasV12 





Figure 3.3 Premature lethality caused by high level of krasV12 expression in 
transgenic zebrafish. (A) Kaplan-Meier survival curves of the Tg(fabp10:EGFP-
krasV12) fish for three groups of heterozygous transgenic zebrafish from F1/Line I (F1/I; n 
= 262), F1/Line II (F1/II; n = 311), F2/Line II (F2/II; n = 356) and WT siblings as control 
(n = 275). (B) Determination of endogenous and transgenic kras expression levels by 
quantitative real-time PCR.  Log2 fold changes for endogenous and transgenic kras 
mRNAs were calculated against an internal housekeeping gene (β-actin) using the CT 
method. Histological analysis was performed to confirm their neoplastic stages before 
qRT-PCR (H, hyperplasia; C, carcinoma; N, normal liver). Results are presented as the 






Figure 3.4 Liver tumors progression in krasV12 transgenic zebrafish. (A-C) Gross 
morphology and histology of WT zebrafish showing normal liver and tissue architecture. 
(D-L) Gross morphology and histology of F2/II krasV12 zebrafish. Brightfield and 
fluorescence (insets) images displaying the progressive stages of liver tumors at 3, 6 and 




arrowheads. Corresponding histological sections are shown in the same rows. Livers 
were observed at 3 mpf (D) and histological appearance revealed multifocal mild to 
moderate cystic degeneration (spongiosis hepatis) and diffused moderate hepatocellular 
hyperplasia (E, F). Many white nodules were developed in transgenic liver at 6 mpf (G) 
and their histology indicated hepatocellular adenoma containing vacuolated clear cells 
with increased cytoplasmic glycogen (H, I). Malignant tumors were visibly observed at 
around 9 mpf (J) and histological analysis confirmed that the tumor was hepatocellular 
carcinoma (HCC) grade II-III (K, L). (M-O) Invasion of HCC cells (indicated by 
arrowheads) into blood vessels (M), and adjacent tissues, namely pancreas (N) and 
kidney (O). Abbreviations: in, intestine; li, liver, sb, swimbladder; te, testis. 





3.1.3  Transplantability of krasV12 liver tumors in WT recipients 
Dissociated HCC cells pooled from four F2/II transgenic zebrafish were injected 
intraperitoneally into 25 sublethally gamma-irradiated WT adult zebrafish (approximately 
1×106 cells per recipient). At 7 days post-injection (dpi), all of the recipients exhibited 
EGFP fluorescence at the site of injection (Figure 3.5A, D). Fluorescence intensified by 
14 dpi and cells appeared to spread to adjacent tissues (Figure 3.5B). At 60 dpi, the tumor 
cells distributed along the abdominal cavity and showed strong EGFP fluorescence at the 
abdominal region in 7 of the recipients (Figure 3.5E). By this time, the outgrowth of the 
tumor mass penetrated through the peritoneal cavity and/or abdominal wall (Figure 3.5C, 





Figure 3.5 Growth of transplanted krasV12 liver tumors inWT recipients. EGFP-
positive HCC cells were transplanted intraperitoneally into irradiated recipients. (A, D) 
EGFP fluorescence was observed near the sites of injection at 7 dpi (days post-injection). 
(B) Transplanted cells proliferated by 14 dpi. (E) Extensive infiltration of tumor cells 
along the peritoneal cavity, especially in the region surrounding the liver (double-headed 
arrow), was observed at 60 dpi. (C, F) The outgrowth of EGFP-positive tumor mass 
(arrowheads) penetrated into the abdominal wall and/or peritoneal cavity at 60 dpi. 





3.1.4  Differential activation of ERK, JNK and p38 mitogen-activated protein 
kinase pathways during krasV12 liver tumorigenesis 
The extracellular signal-regulated kinase (ERK) pathway, one of the most-established 
mammalian MAPK pathways, is commonly activated downstream of Ras.To determine if 
the ERK pathway is activated by overexpression of krasV12, qRT-PCR was conducted to 
analyze the expression of various genes associated with this pathway. 
 Gene expression of the Raf kinases, braf and raf1, and other upstream activators 
of the ERK pathway, namely map2k1, map2k2, map4k2l and map4k5, as well as the 
downstream mapk1 and mapk3, were all up-regulated in both hyperplastic liver (HL) and 
HCC, with higher expression levels in HCC than HL (Figure 3.6A). Transcript levels of 
the other subfamilies of MAPKs were also measured. Level of mapk8 (JNK1) was found 
to increase in both stages. Although an increase in mapk12 (p38γ) and mapk14a (p38α) 
transcripts were observed in HL, their expressions became down-regulated in HCC. A 
similar trend was observed in the transcript level of p38-regulated/activated protein 
kinase (PRAK; mapkapk5). The activation pattern of these three major MAPKs during 
liver tumorigenesis in this transgenic zebrafish model is consistent with those in human 
liver cancer and other HCC models (Figure 3.6B).  
  Next, the protein expression level of Kras in WT normal liver (NWt) and F2/II 
krasV12 transgenic zebrafish having different liver morphologies, including normal liver 
(NTg), HL (H) and HCC (C) (Figure 3.6C), were then evaluated. Western blotting using 
anti-K-Ras (F234) revealed that total Kras was minimal in NWt but increasingly higher in 
NTg, HL and HCC. Immunoblotting with anti-K-Ras-2B (C19) confirmed that no KrasV12 




level as compared to HL and HCC. As Ras signals through MEK and ERK proteins via 
phosphorylation, the levels of P-MEK1/2 and P-ERK1/2 proteins in NTg were shown to 
be similar to those in NWt but were visibly higher in HL and HCC. Indeed, 
immunohistochemistry of liver tumor sections showed apparently enhanced cytoplasmic 






Figure 3.6 Hyperactivation of the mitogen-activated protein kinase (MAPK) 
signaling pathway in krasV12 transgenic zebrafish. (A) Determination of expression 
levels of various kinase genes by qRT-PCR in liver hyperplasia (3 mpf) and carcinoma (9 




first measured and normalized with the expression level of β-actin (n = 5 each). The log2 
fold-changes in expression in the transgenic samples as compared to matched WT sample 
are presented. (B) Comparison of MAPK family expression during liver tumorigenesis in 
krasV12 transgenic zebrafish, human liver cancer and other experimental models of HCCs. 
References are indicated by a for (Schmidt et al., 1997); b for (Wurmbach et al., 2007; 
Chang et al., 2009) and c for (Wurmbach et al., 2007). (C) Western blots of total proteins 
from WT normal liver (NWT) and krasV12 transgenic liver showing normal liver 
morphology (NTg), hyperplastic liver (H) or HCC (C) to detect total K-Ras (F234), K-
Ras2B (C19) isoform, P-MEK1/2 and P-ERK1/2 (also known as phosphorylated p44/42 
MAPK). Arrows: double bands of P-ERK1/2 (44 kDa and 42 kDa). β-actin, internal 
control for equal loading (Western blotting was done by Dr. Vivien Koh). (D) 
Immunohistochemical analysis of paraffin-embedded liver sections from WT (Control; 
top row), 3 mpf transgenic (Hyperplasia; middle row) and 9 mpf transgenic (Carcinoma; 
bottom row) fish. Sections were stained with antibodies against P-MEK1/2 (left column) 





3.1.5  Activation of the Wnt/β-catenin pathway during krasV12 liver tumorigenesis 
Of several signaling pathways frequently deregulated in HCC, the canonical Wnt 
pathway, with β-catenin as a crucial downstream component, is an important contributor 
to tumorigenesis (Farazi and DePinho, 2006). E-cadherin, which is a binding partner of β-
catenin, also plays a critical role in liver tumorigenesis as a tumor/invasion suppressor 
(Wei et al., 2002). To verify activation of the Wnt/β-catenin pathway, 
immunohistochemistry was employed to examine the expression of β-catenin, E-cadherin 
and cellular proliferation marker Ki67 in krasV12 transgenic liver. β-catenin appeared to 
localize in the cell membrane in the WT liver (Figure 3.7A). In contrast, mixed nuclear 
and membranous staining patterns of β-catenin were found in HL with a distinct nuclear 
pattern in HCC. Moreover, HCC showed no staining of E-cadherin, whereas HL retained 
similar E-cadherin staining in the cell membrane as in WT liver (Figure 3.7B). There was 
little or no signal of Ki67 expression in WT liver, while nuclear staining of Ki67 was 
observed in HL and more so in HCC (Figure 3.7C). These data indicate activation of the 






Figure 3.7 Activation of the Wnt/β-catenin pathway during krasV12liver 
tumorigenesis. Representative immunohistochemical liver sections from WT zebrafish 
as the control and krasV12 transgenic fish with liver hyperplasia and carcinoma are shown. 
(A) Immunohistochemistry for β-catenin showing an increasing nuclear localization of β-
catenin during HCC progression. (B)  Immunohistochemistry for E-cadherin showing 
loss of membranous E-cadherin expression during tumor growth. (C) 
Immunohistochemistry for Ki67 showing high expression level of Ki67 in cell nuclei 





3.1.6  Acceleration of liver tumor onset by loss of p53-mediated senescence  
Excessive activation of Ras signaling can induce DNA damage response (DDR) by DNA 
replication stress due to aberrant cell proliferation that could prompt the activation of 
p53-induced senescence as a barrier to tumor progression induced by Ras (DiMicco et al., 
2006; Vousden and Prives, 2009). The senescence-associated β-galactosidase (SA-βgal) 
assay was thus performed on liver cryosections to investigate whether hyperactivation of 
krasV12 could induce senescence. Intense SA-βgal signals were observed only in HL at 3 
mpf, while little signal was detected in HCC at 9 mpf (Figure 3.8A). These observations 
suggested that the number of cells undergoing senescence increased in the pre-neoplastic 
lesions but subsided during progression to the carcinoma stage. Western blotting showed 
that endogenous p53 increased in HL but decreased in HCC (Figure 3.8B). Importantly, 
p21 Waf1/Cip1, a direct transcriptional target of p53 leading to senescence, was elevated 
in HL but decreased in HCC. The level of phosphorylated MDM2 protein, the negative 
regulator of p53, was found to increase in both stages (Figure 3.8B). Collectively, these 
observations verified the response of p53 in mediating senescence in HL resulting in 
latent tumor development. 
 To find out whether loss of p53 could promote tumorigenesis, homozygous 
tp53M214K (tp53-/-) mutant line (Berghmans et al., 2005) was crossed with krasV12 F2/II to 
obtain heterozygous tp53+/- fish expressing krasV12 in the liver. This family was again 
crossed with the tp53-/- line to obtain mixed offspring with tp53+/- and tp53-/- background. 
This cohort was randomly divided and maintained in three tanks. Each tank was 
sacrificed at 3, 6 and 9 mpf to screen for the presence of liver tumors (Figure 3.8C). Liver 
morphology revealed that at 3 mpf, 28% of the tp53-/-zebrafish showed tumor 




observed in the tp53+/- and tp53+/+ siblings at 3 mpf. Notably, SA-βgal assay showed no 
senescence in transgenic tp53-/-fish whereas strong signals were still detected in the 
transgenic fish with tp53+/-background (Figure 3.8D). At 6 mpf, pre-neoplastic tumors 
were observed in the transgenic fish liver with tp53+/+and tp53+/- backgrounds (12% and 
15% respectively). At 9 mpf, liver tumor incidences in the krasV12 transgenics became 
similar, regardless of tp53 status. No significant differences in the survival rates were 
noticed between these cohorts before 90 dpf. Thus, loss of p53 accelerated tumor onset 





Figure 3.8 KrasV12-induced p53-dependent senescence in the pre-neoplastic liver. 
(A) Oncogenic KrasV12-induced senescence at early stage of liver tumor development. 
SA-βgal staining was performed on liver cryosections from 3 and 9 mpf krasV12 
transgenic and WT fish (tp53+/+). (B)  Western blots of total proteins from liver 




suppressor p53 together with its target, p21 Waf1/Cip1, and its regulator, P-MDM2, 
during tumorigenesis. β-actin, internal control for equal loading. (C) Acceleration of liver 
tumor onset in homozygous tp53M214K mutant transgenic fish. Percentages of tumors 
observed from krasV12 transgenic fish with different p53 backgrounds at different time 
points are shown. (D) Suppression of senescence induced by oncogenic krasV12 in tp53-/- 
background.  SA-βgal staining was performed with 4 biological replicates in each group. 




3.1.7  Transcriptomic analyses of krasV12 liver tumorigenesis 
Oligonucleotide microarray was conducted to investigate gene expression profiles in HL 
and HCC as outlined in Figure 3.9. By applying the selection criteria of ≥1.5 log2 fold-
change and p ≤ 0.01 false discovery rate (FDR) adjustment, 1,417 and 1,564 
differentially-expressed genes having human homologues were obtained for HL and 
HCC, respectively. Since a biological process often involves a group of genes acting in 
concert, GSEA (Gene Set Enrichment Analysis) was used to compare predefined human 
gene sets from the Gene Ontology (GO) and KEGG of the Molecular Signature Database 
to gain biological insight into krasV12-driven liver tumorigenesis. Overall, GSEA 
identified 42 and 151 significant human gene sets for zebrafish HL and HCC, 
respectively. Strikingly, activation of key signaling genes were found in HL (p53) and 
HCC (TLR/NF-κB, JAK/STAT, insulin/IGF and TGF-β), as well as in both HL and HCC 
(Raf/MEK/ERK, PI3K/AKT, Wnt/β-catenin, VEGF and complement cascade). GSEA 
also determined the genes within each significantly enriched human set that contributed 
most to the enrichment score in zebrafish HL and HCC. A total of 261 genes in the 42 
hyperplasia gene sets and 598 genes in the 151 HCC gene sets were obtained. These 
genes were then compared with the differentially expressed zebrafish genes to limit to 
only the significantly up- and down-regulated genes. These genes are termed zebrafish 
enriched genes. Hence, 173 up- and 61 down-regulated zebrafish enriched genes were 
found in HL, whereas there were 398 up- and 99 down-regulated zebrafish enriched 
genes in HCC. By overlapping HL and HCC genes, 128, 106 and 391 HL-specific, 







Figure 3.9 Flowchart of microarray data analysis. Step 1: Data acquisition and 
standard data processing. Arrays were scanned for fluorescence signal detection using 
the GenePix 4000B Axon scanner (Molecular Devices, CA) and the generated images 
were analyzed using GenePix Pro® 4.0 image analysis software (Molecular Devices) to 
measure fluorescence signal intensities. All the arrays gave a mean signal-to-background 
ratio of more than 5 and less than 95% of the probes gave measurable signals. Microarray 
raw data were extracted and formatted to conform to the MIAME (Minimal Information 
About a Microarray Experiment) standards, and further subjected to Lowess 
normalization and transformation to log2 ratio using the R system software 
(http://www.R-project.org) (Lam et al., 2009a). Differences between the log2 ratios of 
transgenic and normal livers were calculated to obtain the fold-change values which 
indicate up- or down-regulation in gene expression. Statistical significance of the 
expression level was performed using Student’s t-test to yield the p-value of each gene. 
The resulting p-values were then adjusted for Benjamini and Hochberg false discovery 
rate (FDR) to minimize the number of false positive genes that could be identified by 
chance. Step 2: Identification of differentially-expressed genes having human 
homologues. Zebrafish genes having human homologues and differentially expressed in 




and FDR-adjusted p-value ≤ 0.01 as statistical cut-offs. Step 3: GSEA analysis using 
825 and 200 predefined human gene sets from the GO and KEGG databases 
respectively. GSEA version 2.0.1 from the Broad Institute was used with predefined 
Gene Ontology (GO) and KEGG gene sets retrieved from the GSEA Molecular Signature 
Database (MSigDB v2.5). Detailed description of each gene set can be found at the 
MSigDB website (www.broad.mit.edu/gsea/msigdb/index.jsp). GSEA analysis was 
completed using phenotypic permutation with a weighted enrichment statistic and the 
Ratio_of_Classes metric to rank genes. One thousand permutations of the data were 
completed to obtain a false discovery rate (FDR) q-value. Human gene sets with 
normalized enrichment score (NES) ≥ 1.5, nominal (NOM) enrichment p-value ≤ 0.05 
and FDR q-value ≤ 0.25 were considered significant. The genes within each significant 
human gene set that contributed maximally to the GSEA score in zebrafish hyperplasia 
and HCC were also identified. Step 4: Identification of zebrafish enriched genes 
representing each stage of krasV12 liver tumorigenesis. The zebrafish differentially-
expressed genes having human homologues which satisfied the statistical cut-offs in Step 
2 and the genes obtained by GSEA analysis in Step 3 were then compared to identify the 
genes present in both steps. These genes were termed as zebrafish enriched genes. The 
enriched genes corresponding to each stage of krasV12 liver tumorigenesis were then 
overlapped to obtain the hyperplasia-specific enriched genes, carcinoma-specific 
enriched genes as well as overlapping enriched genes between two stages. Arrows 
indicate up- and down-regulated genes. Step 5: GSEA cross-species comparisons of 
human cancer transcriptomic profiles. Raw data files of different published human 
cancer data sets were obtained from the Gene Expression Omnibus (GEO) database. All 
of the retrieved data sets were generated using the Affymetrix GeneChip® platform. 
Probes with p-call values of < 80% were then discarded across all samples to minimize 
variations from biological samples and identify only reliably measured genes. The lists of 
up- and down-regulated zebrafish enriched genes from Step 4 were used for GSEA cross-
species comparison with these human cancer data sets. Statistical significance of the 
cross-species comparison was determined by the selection criteria of false discovery rate 





3.1.8  Identification of a HCC-specific signature and a liver cancer progression 
signature 
To explore whether the zebrafish stage-specific and overlapping enriched genes in HL 
and HCC possess Ras signature, transcriptomic profiles of human mammary epithelial 
cells (HMECs) infected with activated oncogenes such as β-catenin, E2F3, Myc, Ras and 
Src (Bild et al., 2006) were used for cross-species GSEA analysis. The up-regulated 
zebrafish enriched genes were associated with signatures linked to oncogenic Ras but not 
the other oncogenes (Figure 3.10A). A question was raised at this point whether these 
zebrafish genes were conserved throughout human HCC progression, exclusively at a 
particular stage (cirrhosis, dysplasia and carcinoma) (Wurmbach et al., 2007) or involved 
in other human tumor types. Transcriptomic profiles from different human cancers were 
then used for the comparison. The up-regulated zebrafish HCC-specific enriched genes 
were found to be associated with human liver, pancreatic, colorectal and lung tumors 
(Figure 3.10A). Consistent with this, KRAS mutations are most frequently found in 
human tumors of pancreas, colon, lung and ovary (Karnoub and Weinberg, 2008). Since 
the up-regulated zebrafish HCC-specific enriched genes matched to Ras signature, it may 
explain their association with these human tumor types. A HCC-specific gene signature 
(48 genes) was next defined from a subset of up-regulated HCC-specific zebrafish 
enriched genes that were associated only with human HCC but not with the other tumor 
























Figure 3.10 GSEA identification of conserved gene signatures common between 




cancer transcriptomic profiles with zebrafish up-regulated hyperplasia-specific, 
carcinoma-specific and overlapping enriched genes. Human cancer data sets were 
collected from the Gene Expression Omnibus (GEO) database and their access numbers 
are indicated. Positive normalized enrichment score (NES) indicated enrichment of the 
zebrafish enriched genes in the human tumor state. Results shown in red were statistically 
significant with family-wise error rate (FWER) p-value ≤ 0.05. Significantly matched 
human data sets are underlined and used for gene signature identification by overlapping 
the zebrafish up-regulated carcinoma-specific enriched genes that were found associated 
with each human data set. (B) Venn diagram illustrating the identification of 48 genes 
specific to HCC in both human and zebrafish. The 48 genes are presented in Table 3.1. 
(C) Comprising of the stage-specific and overlapping enriched genes in zebrafish 
hyperplasia and carcinoma respectively used in cross-species GSEA comparisons with 
different human cancer transcriptomic profiles. (D) Venn diagram identification of 20 
genes up-regulated during tumor progression from hyperplasia/dysplasia to carcinoma in 
both zebrafish and human liver cancer. Thses genes are presented in Table 3.2, 





Table 3.1 Potential HCC-specific gene signature restricted only to human HCC. 
Comparison of genes within the up-regulated HCC-specific zebrafish enriched genes as 
identified by GSEA cross-species analysis of different human tumor data sets yielded a 
subset list of 48 genes. These genes were enriched only in human HCC. 
No. Gene Symbol Gene Name 
1 ANGPT1 Angiopoietin 1 
2 APOM Apolipoprotein M 
3 ARRB2 Arrestin, beta 2 
4 CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D subunit 
5 CCL21 Chemokine (C-C motif) ligand 21 
6 CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4 
7 CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase 
8 EIF4A2 Eukaryotic translation initiation factor 4A2 
9 FBXO11 F-box protein 11 
10 GBF1 Golgi brefeldin A resistant guanine nucleotide exchange factor 1 
11 GPR34 G protein-coupled receptor 34 
12 HS6ST1 Heparan sulfate 6-O-sulfotransferase 1 
13 MDM4 Mdm4 p53 binding protein homolog (mouse) 
14 MOBKL1A MOB1, Mps One Binder kinase activator-like 1A (yeast) 
15 MR1 Major histocompatibility complex, class I-related 
16 NPM1 Nucleophosmin (nucleolar phosphoprotein B23, numatrin) 
17 PPP1CB Protein phosphatase 1, catalytic subunit, beta isozyme 
18 RAB3GAP2 RAB3 GTPase activating protein subunit 2 (non-catalytic) 
19 RHOT1 Ras homolog gene family, member T1 
20 RPL10A Ribosomal protein L10a 
21 RPL13 Ribosomal protein L13 
22 RPL18 Ribosomal protein L18 
23 RPL19 Ribosomal protein L19 
24 RPL23A Ribosomal protein L23a 
25 RPL30 Ribosomal protein L30 
26 RPL35 Ribosomal protein L35 
27 RPL4 Ribosomal protein L4 
28 RPL5 Ribosomal protein L5 
29 RPL7 Ribosomal protein L7 
30 RPL7A Ribosomal protein L7a 
31 RPL8 Ribosomal protein L8 
32 RPL9 Ribosomal protein L9 
33 RPS10 Ribosomal protein S10 
34 RPS11 Ribosomal protein S11 
35 RPS18 Ribosomal protein S18 
36 RPS2 Ribosomal protein S2 




38 RPS3 Ribosomal protein S3 
39 RPS5 Ribosomal protein S5 
40 RPS7 Ribosomal protein S7 
41 RPS8 Ribosomal protein S8 
42 SLC25A3 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 3 
43 STAT5B Signal transducer and activator of transcription 5B 
44 STMN1 Stathmin 1 
45 TBX2 T-box 2 
46 TTN Titin 
47 UBE2D2 Ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 






Since each stage of krasV12 liver tumorigenesis contains both stage-specific and 
overlapping enriched genes, cross-species analysis was again performed to assess 
whether HL zebrafish enriched genes, comprising of HL-specific and overlapping genes, 
showed any similarity with early human liver tumorigenesis. Indeed, the up-regulated HL 
enriched genes were significantly associated with human dysplastic liver (Figure 3.10C). 
Similarly, cross-species analysis of HCC-enriched genes revealed that these genes were 
significantly associated with human HCC (Figure 3.10C). By overlapping the up-
regulated HL and HCC enriched genes, a liver cancer progression gene signature, which 
comprises of 20 genes that remained up-regulated throughout human and zebrafish HCC 
progression (Figure 3.10D, Table 3.2), was subsequently identified. In contrast, the 
zebrafish down-regulated enriched genes were not related to any tumor types and 
oncogene status. Similar observations were previously reported in several KrasD12 
transgenic models (Langenau et al., 2007; Sweet-Cordero et al., 2005), suggesting that 
the genes down-regulated by Ras might be different between species and that Ras mostly 
up-regulates gene expression. 
Apart from evaluating the microarray data from hyperplasia and HCC with cross-
species comparisons, qRT-PCR was further performed to confirm the expression of 15 
major genes in several individual lesions from each tumorigenesis stage (Table 3.3). The 
qRT-PCR results closely parallel the microarray data, thus confirming that liver lesions 






Table 3.2 Potential liver cancer progression-associated gene signature. Identification 
of 20 genes from the zebrafish up-regulated enriched genes in both hyperplasia and 
carcinoma stages which remained up-regulated throughout human HCC progression from 
dysplasia to carcinoma. These genes represent potential biological markers associated 
with liver cancer progression. 
No. Gene Symbol Gene Name 
1 APOE Apolipoprotein E 
2 CCNB1 Cyclin B1 
3 CDC25A Cell division cycle 25 homolog A (S. pombe) 
4 DERL1 Der1-like domain family, member 1 
5 MAPK1 Mitogen-activated protein kinase 1 
6 MAPK3 Mitogen-activated protein kinase 3 
7 MAPKAPK2 Mitogen-activated protein kinase-activated protein kinase 2 
8 MCM5 Minichromosome maintenance complex component 5 
9 MDM2 Mdm2 p53 binding protein homolog (mouse) 
10 MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
11 NBN Nibrin 
12 NLK Nemo-like kinase 
13 PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide 
14 PRKCB1 Protein kinase C, beta 
15 RRM2 Ribonucleotide reductase M2 
16 RUVBL2 RuvB-like 2 (E. coli) 
17 SRC v-Src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(avian) 
18 THY1 Thy-1 cell surface antigen 
19 TK1 Thymidine kinase 1, soluble 
20 YWHAB Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 





Table 3.3 Validation of differential gene expression in krasV12 transgenic fish by 
qRT-PCR. Individual lesions from each liver tumorigenesis stage (hyperplastic liver, 
HL; hepatocellular carcinoma, HCC) were examined for the expression level of the major 
genes belonging to several important signaling pathways and processes, including AKT 
(AKT2), ERK (MAPK1, MAPK3, MAPK8, STMN1), STAT (STAT3), p53 (MDM2, TP53), 
TGF-β (TGFB1), WNT (NLK), angiogenesis (ANGPT1), cell cycle (CCNB1, NBN, 
NFYA) and ribosome (RPL19). The log2 fold change obtained from microarray data and 
qRT-PCR for the genes validated are as shown in the table. 
 
No. 
Gene symbol Log2  fold change 
Microarray Quantitative real-time PCR 
Zebrafish Human 






1 akt2l AKT2 1.06 2.91 3.54 2.95 2.78 6.75 5.46 6.03 
2 angpt1 ANGPT1 0.12 2.54 0.26 0.73 0.23 1.58 2.34 1.87 
3 ccnb1 CCNB1 5.48 7.85 5.11 4.12 4.09 9.67 9.46 8.23 
4 mapk1 MAPK1 2.13 2.18 3.28 2.54 4.45 5.79 6.78 6.92 
5 mapk3 MAPK3 2.31 2.64 2.73 1.12 3.67 3.92 4.65 3.75 
6 mapk8 MAPK8 2.09 3.91 2.58 2.56 2.91 4.71 3.56 4.42 
7 mdm2 MDM2 5.66 3.07 2.91 3.40 3.66 3.64 4.07 4.54 
8 nfya NFYA 6.56 1.74 4.83 5.13 5.76 0.47 0.56 0.91 
9 nlk1 NLK 2.16 2.35 1.02 2.34 2.61 1.64 1.07 1.13 
10 rpl19 RPL19 1.20 2.81 2.98 1.45 2.76 4.78 4.75 4.12 
11 stat3 STAT3 -1.06 2.53 -0.67 -1.05 0.12 3.76 3.21 2.65 
12 stmn1a STMN1 -1.30 3.93 -0.59 -0.33 -0.67 4.76 4.12 5.23 
13 tgfb1 TGFB1 0.41 1.88 0.79 0.04 -0.32 3.40 2.11 2.18 
14 tp53 TP53 2.47 -3.54 3.55 2.76 4.29 -0.18 -1.12 -1.56 




3.2 Development and analysis of mifepristone-inducible and -reversible krasV12 
liver tumorigenesis in transgenic zebrafish 
3.2.1  System design 
To improve tumor penetrance and latency as well as overcome the lethal effects of Ras 
during embryonic stage in the previous model (Chapter 3.1), a mifepristone-inducible 
LexPR system (Emelyanov and Parinov, 2008) was employed to temporally control liver-
specific krasV12 expression in transgenic zebrafish. This transgenic system comprises of 
two separate lines as depicted in Figure 3.11A. The liver-driver line, Tg(fabp10:LexPR; 
LexA:EGFP), expressed the LexPR transactivator in the liver under the liver-specific 
fabp10 promoter, which bound to the LexA operator in the presence of mifepristone and 
induced the synthesis of EGFP as a reporter for transgenic identification, as confirmed in 
Figure 3.11B. The second line called Ras-effector, Tg(cryB:mCherry; LexA:EGFP-
krasV12), contained a selection marker, mCherry, driven by the zebrafish crybB (crystallin 
beta B) promoter, which produced red fluorescence in the lens (Figure 3.11C). In the 
Ras-effector line, the expression of the EGFP-krasV12 fusion gene was controlled by 
LexA operator through binding to LexPR transactivator. Crossing the liver-driver and 
Ras-effector lines resulted in double transgenic offspring (Driver/Ras-effector) which 
were capable of expressing EGFP-krasV12 exclusively in the liver upon administration of 
mifepristone (Figure 3.11D). 
To examine the effect of krasV12 expression, F2 Driver/Ras-effector fish were 
treated with 1 µM mifepristone from 3 dpf onwards. At 7 dpf, the liver was greatly 
enlarged with 100% penetrance (Figure 3.11D). In some individuals (less than 5%), some 




abdominal cavity indicating signs of metastasis (Figure 3.11E). Histological analysis 
revealed that early activation of krasV12 caused hyperplastic liver (HL) and early HCC in 
transgenic larvae (Figure 3.11D) as compared to the normal livers in the liver-driver 
alone (Figure 3.11B) and Ras-effector alone controls (Figure 3.11C). Moreover, induced 
larvae started to die from 10 dpf, thus confirming the toxicity and oncogenicity of krasV12 






Figure 3.11 Mifepristone-inducible liver-specific krasV12 expression in transgenic 
zebrafish. (A) Schematic diagram of mifepristone-inducible LexPR system with separate 
liver-driver and Ras-effector constructs. The liver-specific expression of EGFP-krasV12 in 
double transgenic fish (Driver/Ras-effector), harboring both cassettes is activated in trans 
by the LexPR activator produced from the liver-driver in the presence of mifepristone 
(RU486). (B-E) Representative larvae at 7 days post-fertilization (dpf) from the Driver 
(B), Ras-effector (C) and Driver/Ras-effector double transgenics (D, E). All larvae were 
incubated with 1 µM mifepristone from 3 dpf. The upper panels show fluorescent image 
while the lower panels histology. The Driver larvae had induced EGFP expression in the 
liver with a normal liver histology (B). The Ras-effector larvae showed mCherry 
expression in the lens as a transgenic marker but no induced EGFP expression in the liver 
dispalying normal tissue histology (C). EGFP-krasV12 expression was induced in Driver-
effector double transgenic larvae at 3 dpf causing enlarged and hyperplastic liver (D) and 
some individuals showed invasive EGFP-positive cells as indicated by arrows (E). Dotted 






3.3.2  Control of liver tumor progression and regression in krasV12 transgenic 
zebrafish by mifepristone administration 
To avoid oncogenic toxicity during embryonic stage, krasV12 expression was intended to 
switch on in Driver/Ras-effector only at 1-month-old. Mifepristone concentration was 
tested by exposing 1-month-old Driver/Ras-effector fish to 0.1, 0.5, 1, 2 and 5 µM of 
mifepristone (n = 8 in each group). Liver mRNAs from different treated groups were 
isolated after 3 and 7 days of induction, and reverse transcriptase (RT)-PCR was 
performed to detect krasV12 transcripts. As shown in Figure 3.12A, krasV12 transcripts 
were detected in all tested mifepristone concentrations. Notably, increasing dosage of 
mifepristone led to increasing krasV12 transcripts with the highest level obtained at 2-5 
µM. In contrast, no transgenic krasV12 transcript was detected in Driver/Ras-effector in 
the absence of mifepristone. To demonstrate the feasibility of switch-off of krasV12 
expression by mifepristone removal, Driver/Ras-effector fish induced in 2 µM 
mifepristone for 3 days were transferred to mifepristone-free water. RT-PCR analysis 
indicated that transcription of krasV12 in these fish can be completely switched off after 7 
days withdrawal of mifepristone (Figure 3.12A). However, reduced krasV12 transcript was 
still detected in the Driver/Ras-effector fish exposed to 2 µM mifepristone for a longer 
exposure of 7 days, following 7 days of mifepristone withdrawal. These results indicated 
that the switch-off delay can be shortened by decreasing the length of exposure.  
To confirm optimal mifepristone concentrations in inducing krasV12 liver 
tumorigenesis, different groups of 1-month-old Driver/Ras-effector (n = 20 in each 
group) were treated with several mifepristone concentrations for at least 6 months to 




dependent induction of liver tumors. While the low dosage required longer times and had 
lower frequency for liver tumors, both 2 and 5 µM groups showed full tumor penetrance 
(100%) after 1 month of mifepristone induction. Since there was no significantly 
difference in tumor penetrance and latent time between 2 and 5 µM mifepristone, 2 µM 
mifepristone was chosen for further experiments.  
Next, detailed study of krasV12-induced tumor progression was conducted on 100 
Driver/Ras-effector fish maintained in water containing 2 µM mifepristone. Gross 
morphological and histological analyses were weekly performed on 15 randomly selected 
Driver/Ras-effector to monitor tumor development. These analyses showed robust 
tumorigenesis starting from HL to full-blown HCC within 4 weeks of induction (Figure 
3.12C). During tumor progression, increasing liver tumor volume was observable by 
strong EGFP fluorescence. Strikingly, 100% of induced Driver/Ras-effector fish 
developed HL after 1 week and then progressed to homogeneous HCC after 4 weeks 
(Figure 3.12D). Notably, no adenoma was observed in induced transgenics.  
To find out if tumor maintenance requires continual krasV12 expression, a group of 
15 Driver/Ras-effector with HCC was transferred to mifepristone-free water. Results 
showed that mifepristone withdrawal led to liver tumor regression with gradual loss of 
EGFP fluorescence (Figure 3.12E). Histological examination revealed tumor shrinkage 
showing extensive scarring at the peripheral or focal tumor region in 100% of 
Driver/Ras-effector fish. Notably, complete tumor regression with scarred fibrosis of the 
former tumor tissue was observed after 4 weeks withdrawal of mifepristone. On the other 
hand, continual treatment of Driver/Ras-effector until 8 weeks resulted in extensive 




and even ascites or invasive HCC (Figure 3.13A, B). At this stage, the time required for 
tumor regression was lengthened and 5-10% of induced transgenics showed non-
regressed tumors. In contrast, the non-induced Driver/Ras-effector fish remained as 






Figure 3.12 Dosage-dependent induction of krasV12 expression and liver tumor 
induction and regression. (A) RT-PCR analysis of transgenic krasV12 transcripts in liver 
of 1-month-old Driver/Ras-effector double transgenic larvae after 3 (left) and 7 days 
(right) of RU486 induction at different concentrations. Time- and dose-dependent 
treatment with mifepristone affected the level of krasV12 transcripts and the time required 
for down-regulation of krasV12 after RU486 withdrawal (off) in Driver/Ras-effector. 
Induced and non-induced driver transgenics together with non-induced Driver/Ras-




induction rates for 1-month-old Driver/Ras-effector fish that were treated with different 
concentrations of RU486 (n = 20 in each group). (C) Statistics of tumor incidence by 
histopathological analysis on induced Driver/Ras-effector from 1-4 weeks of 2 µM 
RU486 treatment. (D) Liver tumor progression in Driver/Ras-effector fish induced by 2 
µM mifepristone. Four panels represent different stages of liver tumorigenesis starting 
from hyperplastic liver (HL) (2 weeks), HCC (4 weeks) and hepatoblastoma in mixed 
HCC (8 weeks). Each panel contains brightfield and fluorescent images of gross liver 
morphology (top) and relevant histological image (bottom). (E) Liver tumor regression 
after mifepristone withdrawal. Driver/Ras-effector following treatment of 2 µM RU486 
for 4 weeks developed EGFP-labeled HCC and their exposure to RU486 were then 
terminated. Histological sections from two representative fish after RU486 removal for 2 
and 4 weeks are shown. Dotted areas showed tumor shrinkage with marked peripheral 
scarring formation whereas asterisks indicated surrounding normal hepatic tissue. (+) and 






Figure 3.13 Advanced liver cancer in krasV12 transgenic fish. Morphological and 
histological examinations of liver tumors in Driver/Ras-effector fish induced with 
mifepristone (RU486) longer than 8 weeks. Representative brightfiled and fluorescent 
images of liver morphology and histology of induced fish are shown. (A) 
Histoplathological analysis revealed that hepatoblastoma (dotted area) which is made up 
of undifferentiated cells with large nuclei developed in mixed carcinoma in Driver/Ras-
effector fish approximately 8 weeks of induction. In addition, these fish also showed 
invasion of tumor cells into blood vessels. (B) More than 8 weeks of mifepristone 
induction, 10% of induced Driver/Ras-effector fish developed cyst fluid or malignant 
ascites in HCC. Detached HCC cells were found in the cysts and blood vessels. Black 




3.2.3  Activation of ERK and AKT pathways required for krasV12-driven liver 
tumorigenesis and tumor maintenance 
To assess whether Raf/MEK/ERK pathway is a major Ras downstream effector involved 
during liver progression and regression in the current model, Western blot analysis was 
carried out using liver lysates from four groups: Control (non-induced Driver/Ras-
effector with normal liver), HL (induced Driver/Ras-effector for 2 weeks), HCC (induced 
Driver/Ras-effector for 4 weeks) and regressed HCC (induced Driver/Ras-effector for 4 
weeks following 2 weeks of mifepristone withdrawal) (Figure 3.14A). Immunoblotting 
with anti-K-Ras (F234) for total Kras protein and anti-K-Ras-2B (C19) for KrasV12 
mutant showed that overexpression of KrasV12 protein was only observed in HL and HCC 
as compared to Control. Due to the strong induction, low level of KrasV12 was still 
detected in the regressed HCC. Consistent with KrasV12 levels, P-ERK1/2 protein was 
elevated in HL and HCC but decreased during tumor regression due to down-regulation 
of KrasV12. Apart from the ERK pathway, the phosphatidylinositol-3 kinase (PI3K) is 
another well-characterized effector of Ras. Activation of PI3K/AKT leading to increased 
phosphorylation of AKT that activates mTOR and then phosphorylates the ribosomal 
protein S6 as their downstream regulator has been well-illustrated in cancer (Downward, 
2003). Immunoblotting using anti-P-AKT and anti-P-S6 showed elevated levels of these 
proteins in krasV12 HL and HCC whereas their expressions were decreased during tumor 
regression. Immunohistochemistry further confirmed the hyperactivation of these two 
pathways associated with krasV12 liver tumor progression (Figure 3.14B). In the regressed 
HCC, while reduced P-ERK1/2 and P-AKT stainings were observed in the remaining 




that tumor scar contained abundant cell death due to inactivation of Ras signaling causing 



















Figure 3.14 Roles of Raf/MEK/ERK and PI3K/AKT/mTOR pathways during 
krasV12 tumor progression and regression. (A) Western blots using total liverprotein 
from induced Driver/Ras-effector with hyperplastic liver (HL) and hepatocellular 
carcinoma (HCC) as well as regressed HCC to detect total K-Ras (F234), mutant K-
Ras2B (C19) isoform, P-ERK1/2, P-AKT and P-S6 proteins. The non-induced driver, 
induced-driver and non-induced Driver/Ras-effector having normal liver (N) all served as 
controls. β-actin, internal control for equal loading. (Western blotting was done by Dr. 
Vivien Koh). (B) Immunohistochemical staining showing the phosphorylation state of 
ERK1/2 and AKT protein during krasV12-dependent liver tumor progression and 
regression. TUNEL staining detecting cell death in the indicated sections. Asterisks 






3.2.4  Prevention of krasV12 liver tumorigenesis by inhibiting ERK and/or AKT 
pathways 
To further investigate the molecular mechanisms of krasV12-induced 
hepatocarcinogenesis and to demonstrate the potential of the transgenic model for 
possible anti-cancer drug screening, several inhibitors targeting ERK and/or AKT 
pathways were selected to validate the involvement of these key signaling pathways. 
Generally, the mifepristone-induced Driver/Ras-effector larvae were co-treated with 
mifepristone and inhibitor(s) at 3-3.5 dpf, and liver morphology was then examined at 7 
dpf under fluorescent microscope. To evaluate inhibitor efficacy, liver size of treated 
larvae was classified into three categories as “normal” (liver size comparable to normal 
liver in driver transgenics), “huge” (the liver remained hyperplastic) and “large” liver 
(larger than normal liver but smaller than HL) (Figure 3.11B, D). As shown in Figure 
3.15A and B, treatment with MEK1/2 inhibitors, PD98059 at 10 µM, resulted in the 
inhibition of hyperplastic liver growth in 49 of krasV12 transgenic larvae. Similarly, 
inhibition of PI3K/AKT/mTOR signaling by targeting either PI3K with 10 µM 
LY294002 or mTOR with 0.7 µM Rapamycin also recovered the “normal” liver 
phenotype to 57% or 69%. However, these results implied that inhibition of solely 
Raf/MEK/ERK or PI3K/AKT/mTOR pathways was insufficient to completely suppress 
the hyperplastic liver induced by krasV12. Thus, co-treatment of PD98059 and LY294002 
or PD98059 and Rapamycin was performed to dually inhibit these two pathways. Results 
revealed that blocking both kinases led to a more pronounced anti-tumorigenic effect (78-
96% of treated krasV12 larvae with “normal” liver) (Figure 3.15A, B). Western blotting 




lysates (Figure 3.15C). Although all inhibitors significantly inhibited their targets, 
blockage of Raf/MEK/ERK or PI3K/AKT/mTOR alone did not affect the other. The 
combination of both PD98059 and LY294002 showed a substantial decrease in P-ERK, 
P-AKT and P-S6 levels. However, only P-ERK and P-S6 levels were suppressed when 
PD98059 and Rapamycin were used in co-treatment. Collectively, these results implied 
that both Raf/MEK/ERK and PI3K/AKT/mTOR pathways need to be inhibited for 







Figure 3.15 Suppression of liver tumorigenesis by inhibition of Raf/MEK/ERK and 
PI3K/AKT/mTOR pathways. (A) Fluorescent images showing representative 
mifepristone-induced EGFP-krasV12 Driver/Ras-effector larvae at 7 dpf treated with 
different inhibitors as compared to the DMSO-treated driver and Driver/Ras-effector 
transgenics as controls. Scale bar, 200 µm. (B) Comparison of anti-hyperplastic liver 
effect of inhibitors in transgenic larvae at 7 dpf. The liver size of treated larvae was 
classified as “normal” if same as the liver in driver transgenics, “huge” if it remains 
enlarged/hyperplasia, or “large” if it is larger than normal liver, but smaller than 
hyperplasia after 4 days of inhibitor treatment. (C) Lysates extracted from whole 
transgenic larvae treated with indicated inhibitors were immunoblotted for P-ERK, P-




3.3  Development and analysis of mifepristone-inducible Cre recombination to 
conditionally control krasV12 liver tumorigenesis in transgenic zebrafish 
3.3.1  System design 
A major disadvantage of the mifepristone-inducible system described in Section 3.2 is the 
requirement of continued presence of chemical inducer in order to maintain the tumor 
phenotype that is often inconvenient to perform some long-term experiments and future 
drug screening. Thus, a combination between mifepristone-inducible and Cre/loxP 
recombination systems was generated to temporally control the expression of krasV12 to 
induce liver tumors in zebrafish. This approach involved the generation of three distinct 
constructs including Liver-driver, Cre-effector and LChL-Ras as outlined in Figure 3.16. 
The driver line is the same line as used in the mifepristone-inducible system (Section 3.2) 
(Figure 3.16A). The second construct is known as the Cre-effector, Tg(cryB:mCherry; 
LexA:Cre), where NLS-Cre (nuclear localization sequence-Cre recombinase) expression 
is under the control of LexA operator. The Cre-effector also contained a selection marker, 
mCherry, which is driven by the zebrafish crybB (crystallin beta B) promoter to give a 
red fluorescence in the lens (Figure 3.16B). By crossing the liver-driver line with the Cre-
effector line, double transgenic offspring called the Driver/Cre-effector was obtained and 
is capable of expressing the Cre recombinase in liver upon the administration of 
mifepristone (Figure 3.16C). To carry out the Cre-mediated conditional expression of 
krasV12, the third construct Tg(fabp10:loxP-mCherry-loxP-EGFP-krasV12) called LChL-
Ras was then engineered (Figure 3.16D). In this construct, the fabp10 promoter drove 
liver-specific expression of the mCherry gene, followed by the transcriptional STOP 




downstream of a floxed mCherry-STOP cassette, preventing the transcription of EGFP-
krasV12 from the upstream fabp10 promoter. Triple transgenic fish (Triple-Tg) harboring 
three different constructs, including the liver-driver, Cre-effector and LChL-Ras were 
obtained by crossing the LChL-Ras line to the Driver/Cre-effector line (Figure 3.16E). 
Upon the application of mifepristone, Cre was exclusively expressed in the liver of 
Triple-Tg fish, thus directing genomic DNA recombination. Removal of the mCherry-
STOP cassettes flanked by the two loxP sites resulted in the irreversible expression of 
EGFP-krasV12 in the liver. In this system, all of the constructs possess the Ds cis-required 







Figure 3.16 Strategies for the mifepristone-induced Cre-mediated conditional 
expression of krasV12 in transgenic zebrafish. Scheme of DNA construct and 
fluorescent image of transgenic fish carrying the relevant construct are shown in the same 
box. (A) Liver-driver line expressing EGFP in the liver as a transgenic reporter in the 
presence of mifepristone (RU486). (B) Cre-effector line containing a mCherry coding 
sequence as a selection marker under control of the crybB promoter and a fused NLS-Cre 
gene under control of the LexA operator. (C) Double transgenic fish (Driver/Cre-effector) 
obtained by crossing the Liver-driver line with the Cre-effector line. (D) LChL-Ras line 
harboring a fabp10 promoter-driven EGFP-krasV12 fusion gene trancriptionally 
interrupted by loxP-flanked mCherry followed by a STOP cassette. (E) Triple transgenic 
fish (Triple-Tg) containing three different constructs obtained via crossbreeding of the 
Driver/Cre-effector line with LChL-Ras line. By applying RU486 to Triple-Tg fish, 
LexPR activator generated from the driver exclusively activates Cre expression in the 
liver, which subsequently removes DNA sequences coding mCherry-STOP flanked by 
the two loxP sites. After Cre-mediated recombination, the liver-specific expression of 





3.3.2  Determination of concentration- and time-dependent mifepristone induction 
of Cre expression 
Previous data in Section 3.1 and 3.2 indicated that early expression of krasV12 during the 
embryonic stage strongly affected the normal process of liver morphogenesis, 
subsequently decreasing transgenic survival rate. To overcome this problem in the 
present model, the expression of krasV12 was temporally switched on via Cre 
recombination in 1-month-old Triple-Tg fish. First, to determine the expression of Cre 
recombinase, the Driver/Cre-effector fish were induced for various durations with several 
concentrations of mifepristone. Induction for at least 24-48 h with 1 or 2 μM mifepristone 
showed efficient expression of Cre RNA in Driver/Cre-effector transgenics as examined 
by one-step RT-PCR (Figure 3.17A). Protein levels of Cre were also determined by 
Western blotting using anti-Cre antibody. One-month-old Driver/Cre-effector fish were 
treated specifically with 1 μM mifepristone for 0, 12, 24, 36 or 48 h. Liver lysate samples 
were assessed for Cre protein expression 24 h post-treatment (Figure 3.17B).  From 24-
48 h of induction, high level of Cre expression was observed, which correlated with the 
length of mifepristone exposure. Therefore, treatment with 1 μM mifepristone for 36 h 
was selected as an effective condition to induce Cre recombinase in 1-month-old Triple-
Tg fish (Figure 3.17B).  In contrast, Cre protein was undetected in both untreated 
Driver/Cre-effector and Triple-Tg or LChL-Ras transgenics with or without induction 
(Figure 3.17B), indicating the tight control of this system. The feasibility of Cre-mediated 
recombination occurring at the two loxP sites of the loxP-mCherry-loxP cassette was 
verified by PCR assay (Figure 3.17C). To carry out the assay, 1-month-old heterozygous 




effector and red liver for the LChL-Ras. As there was no selective marker for the Driver 
line without induction, PCR based genotyping assay was used to confirm fish positive for 
this construct. At one wpi, liver genomic DNA was extracted from treated and untreated 
Triple-Tg fish to perform PCR with three primers to examine the excision (Figure 
3.17C). All of the treated Triple-Tg fish (n = 22) showed efficient recombination at the 
DNA level, whereas no excision happened in non-treated Triple-Tg fish (n = 5). Notably, 
incomplete excision exhibited in most of the mifepristone-treated Triple-Tg fish tested by 






Figure 3.17 Optimization of Cre expression mediated by mifepristone in 1-month-
old transgenic fish. (A) One-step RT-PCR determining Cre transcription induced by 
different mifepristone conditions in Driver/Cre-effector fish (n = 3 per condition). (B) 
Western blot detecting Cre protein expression in liver of 1-month-old Driver/Cre-effector 
and Triple-Tg fish harboring Driver, Cre-effector and LChL-Ras contructs upon 1 μM 
mifepristone stimulation at several durations (n = 3 fish per time point). β-actin was used 
as loading control. (C) Diagram of the loxP-mCherry-loxP-EGFP-kras construct and the 
location of the three primers, depicted by colored arrows, used to demonstrate excision of 
the loxP-flanked sequences. A 1050 bp (base pair) fragment amplified by two primers 
(black and green arrows) indicated successful Cre excision resulting in deletion of floxed 
mCherry-STOP sequences. In contrast, the combination of “black and red” primers 
amplifies a 793 bp fragment indicating non-excision. (D) PCR assay for Cre-mediated 
recombination using liver genomic DNA of the mifepristone treated (+) or untreated (-) 
Triple-Tg and LChL-Ras fish. Non-excision showed one lower band while complete 
excision gave a single upper band and incomplete excision showed both bands on the 




3.3.3  Mosaicism of EGFP-krasV12 expression in Triple-Tg fish causing 
hepatocellular carcinoma and other types of liver tumor  
In principle, a complete recombination event of the loxP-mCherry-loxP cassette is 
observable using fluorescence microscopy by monitoring the loss of red fluorescence and 
the appearance of green fluorescence from the EGFP-krasV12 gene in the liver of induced 
Triple-Tg fish. This approach was subsequently confirmed not only for successful Cre 
excision, but also for monitoring liver tumor formation. To demonstrate tumor formation 
in this inducible system, a cohort of 60 1-month-old heterozygous Triple-Tg fish was 
induced for 36 h with 1 μM mifepristone, while their non-induced Triple-Tg (n = 30) and 
LChL-Ras transgenics (n = 30) served as controls (Figure 3.18A-C). By 2 wpi, EGFP-
labeling cells started to grow in the liver of induced Triple-Tg fish (Figure 3.18D-E) and 
progressed to liver tumors within 4-24 wpi (Figure 3.18F-K). In line with the PCR assay, 
82% of induced Triple-Tg fish (32 out of 39) developed liver tumors and showed partial 
excision as livers exhibited both red and green fluorescence (Figure 3.18D-K), whereas 
complete excision only happened to 12% (7 out of 39) (Figure 3.18L-Q). Nevertheless, 
most liver tumors (93%, 40 out of 43) only exhibited EGFP expression, indicating 
complete excision that was confirmed by PCR. No EGFP-KrasV12 expression and tumor 
development could be detected in the controls (Figure 3.18A-C), which were further 
confirmed by histological analyses (Figure 3.19A, B). Notably, detailed histopathological 
analyses of the 39 fish revealed that Triple-Tg fish overexpessing krasV12 developed 
various liver tumors, which fall into 3 main lesions including hepatocellular adenoma 
(HCA) (36%, 14/39), HCC (82%, 32/39) and hepatoblastoma (HB) (8%, 3/39) (Table 




ranging from benign to malignant cancer with occasional HCC arising in HCA (8%, 
3/39) (Figure 3.19C, D), mixed HCC (Figure 3.19G, H) and HB arising in HCC (8%, 
3/39) (Figure 3.19G, H), all suggesting ongoing liver cancer progression in induced 
Triple-Tg fish. 
To assess the influence of age on tumor incidence, two other groups of Triple-Tg 
fish at 3-month-old (n = 40) and 6-month-old (n = 38) were exposed to mifepristone 
using similar treatment conditions (1 μM mifepristone for 36 h) as the 1-month-old 
Triple-Tg zebrafish. Kaplan-Meier analysis revealed that the highest tumor incidence was 
achieved in the induced 1-month-old Triple-Tg fish (65%,  39 out of 60) as compared to 
Triple-Tg fish induced at 3-month-old (33%, 13 out of 40) and 6-month-old (18%, 7 out 
of 38) (Figure 3.20). Moreover, highest rate of tumor induction was also obtained in 1-







Figure 3.18 Mosaic pattern of Cre-mediated activation of EGFP-KrasV12 in 
transgenic fish. Brightfield and corresponding fluorescence images of representative 
Triple-Tg fish are shown in the same rows. (A-C) Without induction, Triple-Tg fish 
showing normal liver morphology (A) with mCherry (B) but not EGFP-KrasV12 (C). (D-
K) Induced Triple-Tg fish at 1-month-old expressing both mCherry (D, G, J) and EGFP-
KrasV12 (E, H, K) in the liver, indicating the occurrence of incomplete Cre excision. After 
induction, many subsets of EGFP-positive liver cells were observed in 1.5-month-old fish 
(D, E). Liver tumors expressing EGFP developed in a 2.5-month-old (F, G, H) and 6-
month-old Triple-Tg fish (I, J, K). (L-Q) Complete excision of the LChL cassettes 
observed in induced Triple-Tg fish at 6-month-old with the formation of large liver 
tumors (L, O) only expressing EGFP-KrasV12 (N, Q) and no detectable mCherry 





Figure 3.19 Heterogeneous liver tumors induced by krasV12. Histopathological 
examinations of liver tumors from Triple-Tg fish induced at 1-month-old. (A, B) 
Representative normal liver section from Triple-Tg fish without induction. (C, D) Liver 
tumor from induced Triple-Tg fish after 15 weeks displayed many vacuolated 
hepatocellular adenoma (HCA) with carcinoma grade 2 (HCC) arising in the center. (E, 
F) Liver tumor from induced Triple-Tg fish after 19 weeks showed HCC (grade 1) 
occupying 80% of the liver volume, with HCC (grade 2) arising centrally. (G, H) A 
Triple-Tg fish at 28 weeks after induction showing HCC (grade 2-3) involving the entire 
liver with extensive areas of hepatoblastoma (HB). Right panel showed high 
magnification of boxed area in the left panel. Arrows indicated the boundaries between 
different types of liver tumors. Scale bars, 100 μm. (Histopathological analysis was done 





Figure 3.20 Early induction of krasV12 caused high penetrance of liver tumors. 
Kaplan-Meier analysis identified tumor incidence and tumor induction rates of the Triple-
Tg fish treated with 1 µM mifepristone (RU486) for 36 h at 1-month-old (n = 60; p < 
0.0001), 3-month-old (n = 40; p = 0.0053) and 6-month-old (n = 38; p = 0.0448) as 





Table 3.4 Histopathologic findings in Triple-Tg zebrafish overexpressing krasV12 in 
liver since 1-month-old (diagnosed by Dr. Jan Spitsbergen) 
No. Wpi Histological diagnoses of liver tumors 
1 4 Adenoma 2 mm 
2 4 Adenoma 2 mm 
3 4 Adenoma 2 mm with Carcinoma arising in the center 
4 5 Carcinoma involving entire liver 
5 9 Adenoma 2 mm and Carcinoma 2 mm 
6 9 Adenoma 2 mm 
7 9 Adenoma 4 mm 
8 9 Adenoma 4 mm with Carcinoma arising in the center 
9 9 Adenoma 1 mm and Carcinoma 4 mm 
10 9 Carcinoma involving entire liver 
11 9 Carcinoma involving entire liver 
12 15 Adenoma 2 mm with and Carcinoma arising in the center 
13 15 Adenoma 1 mm and Carcinoma 4 mm 
14 15 Carcinoma occupying 80% of liver 
15 15 Carcinoma 4 mm 
16 15 Carcinoma involving entire liver 
17 15 Carcinoma involving entire liver 
18 17 Adenoma 4 mm 
19 17 Carcinoma 4 mm 
20 17 Adenoma 1 mm and Carcinoma 3 mm 
21 19 Carcinoma 4 mm 
22 19 Carcinoma 3.5 mm 
23 19 Carcinoma involving entire liver 
24 19 Carcinoma involving entire liver with blood vessel invasion 
25 19 Carcinoma occupying 80% of liver 
26 19 Carcinoma 2 mm 
27 19 Carcinoma occupying 90% of liver 
28 19 Carcinoma involving entire liver with foci of Hepatoblastoma 
29 19 Carcinoma involving entire liver with foci of Hepatoblastoma 
30 19 Carcinoma 4 mm 
31 19 Carcinoma 4 mm 
32 19 Carcinoma occupying 80% of liver 
33 19 Carcinoma 4 mm 
34 23 Adenoma 4 mm 
35 23 Adenoma 2 mm 
36 23 Carcinoma 4 mm with blood vessel invasion 
37 23 Carcinoma 4 mm 
38 23 Carcinoma 4 mm 




3.3.4 Deregulation of ERK and Wnt/β-catenin pathways during krasV12-induced 
liver tumor progression 
Since mosaic activation of oncogenic krasV12 caused various liver tumor types in the 
current system, its molecular mechanism of krasV12-driven liver tumorigenesis might be 
different from the other two systems described in Sections 3.1 and 3.2. To investigate this 
hypothesis, immunohistochemical analyses were conducted to examine the activation of 
the ERK and Wnt/β-catenin signaling pathways in benign and malignant krasV12 liver 
tumors. As shown in Figure 3.21A, all of the liver tumor types (HCA, HCC and HB) 
showed ubiquitous activation of ERK1/2, as evident by intense cytoplasmic and nuclear 
staining of P-ERK1/2. However, stronger signals of P-ERK1/2 were detected in 
malignant HCC and HB than HCA. Strikingly, immunohistochemistry identified mostly 
membranous and no obvious nuclear staining of β-catenin in HCA, which was similar to 
normal liver (Figure 3.21B). In contrast, HCC and HB only exhibited positive β-catenin 
in the nuclei. These findings suggested that activation of Wnt/β-catenin via the 
accumulation and translocation of β-catenin into the cell nucleus is required for malignant 







Figure 3.21 Deregulation of ERK and Wnt/β-catenin pathways in different types of 
krasV12-induced liver tumors. Three types of liver neoplasia including benign HCA, 
malignant HCC and HB were examined for the expression patterns of P-ERK1/2 and β-
catenin via immunohistochemistry. (A) Strong mixed nuclear and cytoplasmic staining of 
P-ERK1/2 was detected in three types of krasV12 liver tumor as compared to control liver 
of uninduced Triple-Tg fish. (B) Immunohistochemistry for β-catenin showed nuclear 
localization and accumulation of β-catenin only in HCC and HB, whereas normal liver 











4.1 A high level of krasV12 expression leading to HCC in transgenic zebrafish  
In the section 3.1 of the project, the first in vivo zebrafish model of liver tumorigenesis 
driven by constitutive expression of oncogenic krasV12 has been generated. Experimental 
data proved that the expression level of krasV12 is a critical determinant of liver 
tumorigenesis through hyperactivation of the Raf/MEK/ERK pathway, as only the 
transgenic fish which exhibited higher krasV12 level showed activation of ERK signaling 
and progression of liver tumor from hyperplasia (HL) to benign and invasive HCC. 
Although JNK and p38 MAPK were activated coordinately in HL, they were differently 
deregulated in HCC with the down-regulation of p38 MAPK and up-regulation of JNK. 
This is reminiscent of an earlier report that hepatocyte-specific deletion of p38α promotes 
liver carcinogenesis with correlated activation of JNK (Hui et al., 2007). Furthermore, 
p38/PRAK could also activate p53 in response to oncogenic Ras to mediate cellular 
senescence (Sun et al., 2007). Besides MAPKs, overexpression of Ras can initiate 
multiple signal transduction pathways implicated in tumorigenesis, as summarized in 
Figure 4.1. Activation of PI3K/AKT, VEGF and Wnt/β-catenin pathways as well as the 
complement cascade was consistently observed in zebrafish HL and HCC, underscoring 
the importance of these signaling pathways during liver tumorigenesis. It is also well-
known that the complements act as pro-inflammatory factors as part of immune 
surveillance. Markiewski et al. (2008) suggested that tumor-induced complement system 
could enhance tumor growth by modulation of the anti-cancer immune response. As such, 
this transgenic zebrafish model confirms the role of complements in HCC development. 
Analysis of stage-specific liver lesions revealed the activation of DNA replication 




oncogene-induced senescence (OIS). Replicative DNA damage triggered senescence 
through the p53 pathway. The increase of p53 then imparts its tumor suppressive effects 
through the induction of p21 to stall the cell cycle (Vousden and Prives, 2009). The 
nuclear transcription factor Y subunit alpha gene, nfya, previously proposed as a marker 
specifically associated to OIS by Collado et al. (2005), was extremely up-regulated in 
krasV12 HL. The list of enriched genes corresponding to HL as identified by GSEA in this 
study may thus yield new useful markers for the detection of senescence. Deleterious 
TP53 mutations enhanced hepatocarcinogenesis while restoration of TP53 induced 
senescence that led to HCC regression (Takai et al., 2009; Xue et al., 2007). Results 
showed that tp53 null mutation can accelerate HCC onset marked by the abrogation of 
OIS in krasV12 zebrafish. However, tumor incidence did not increase in tp53-/-/krasV12 
zebrafish. These observations support previous finding that TP53 mutation is a late event 
in human HCC (Martin and Dufour, 2008). Moreover, HCC is rarely found in tp53-/- 
zebrafish and Tp53 knockout mice alone (Berghmans et al., 2005; Donehower et al., 
1992; Parant et al., 2010). Even in the absence of tp53, low expression of krasV12 seemed 
insufficient to initiate liver tumorigenesis. This proposes that low levels of Ras require 
multiple mutations for neoplastic initiation in the liver.  
Interestingly, in the sequence of events leading to HCC, the up-regulation of two 
important transcription factors linking inflammation and cancer, namely NFKB and 
STAT3 (Mantovani et al., 2008), were also observed. TLR, which is an essential upstream 
regulator of NFKB, and the JAK/STAT pathway were significantly activated only in 
krasV12 HCC. The synergistic activities of NFKB and STAT3, together with the 




Therefore, inhibition of inflammation should be considered as a valuable strategy for 
HCC prevention. Furthermore, the emergence of JAK/STAT, IGF and TGF-β pathways, 
as well as loss of E-cadherin in krasV12 HCC, contributed to tumor cell growth, survival 
and invasion. This finding highlighted the significance of these pathways in HCC 





Figure 4.1 Proposed mechanism of Ras-induced liver tumorigenesis in transgenic 
zebrafish model. High level of KrasV12 in the zebrafish liver leads to the activation of 
several key signaling pathways implicated in liver tumorigenesis, showing signaling 
pathways significantly activated in HL (blue), in both HL and HCC (red), and in HCC 
(green). During early tumorigenesis, the Raf/MEK/ERK, JNK, PI3K/AKT and Wnt/β-
catenin pathways drive proliferation, whereas Raf/MEK/ERK, PI3K/AKT and VEGF 
signaling induces angiogenesis and complement cascade induces inflammation. Crosstalk 
among these signaling activates the three major processes, proliferation, angiogenesis and 
inflammation, leading to liver hyperplasia. Another mechanism upon expression of 
KrasV12 was the deregulation of p38 MAPK signaling. In HL, p38 MAPK was up-
regulated, leading to the activation of PRAK and subsequently p53, which then targets 
the downstream p21 to mediate cellular senescence. In addition, aberrant cell 
proliferation could also induce DNA damage, which might further prompt the up-
regulation of p53. Moreover, DNA damage triggers DNA repair, enabling hyperplastic 
cells to overcome such damage. Thus, oncogene-induced senescence acts as a p53-
dependent tumor-suppressive mechanism in the pre-neoplastic stage to guard against 
tumor progression. Down-regulation of p38 MAPK, together with persistent high level of 
MDM2 that might eventually result in a reduction in p53, could also serve as alternative 
mechanisms for liver tumorigenesis to bypass senescence. In HCC, activation of 
JAK/STAT and TLR/NF-κB pathways enhance the inflammatory process. Importantly, 
the consistent activation of proliferation, angiogenesis and inflammation with their 
involved pathways, together with activation of the JAK/STAT, insulin/IGF and TGF-β 
pathways, are essential for contribution to tumor cell growth, survival and invasion. Loss 
of key tumor suppressors, p53 and E-cadherin, further characterize malignant/invasive 




4.2  Conserved gene expression signatures underlying liver tumorigenesis in 
humans and krasV12 transgenic zebrafish  
Microarray and GSEA analyses using the transgenic liver tumors constituitvely 
expressing krasV12 uncovered two gene signatures, one being a HCC-specific signature 
and the other associated with a liver cancer progression signature.  Both are up-regulated 
in human and zebrafish liver cancer, underscoring the molecular conservation across 
vertebrates. Several genes in these two gene signatures have been reported as prognostic 
markers for human HCC, for example ANGPT1 and STMN1 in the HCC-specific 
signature, and APOE and CCNB1 in the HCC progression signature (Torimura et al., 
2004; Wong et al., 2008; Wurmbach et al., 2007; Yokoyama et al., 2006). Interestingly, a 
large family of ribosomal proteins contributed to the bulk of the HCC-specific signature. 
Previously, Lee et al. (2004) demonstrated a consistent elevation of ribosomal proteins in 
human and mouse liver cancers. The present study additionally highlights the possibility 
that ribosomal proteins might serve as evolutionarily conserved markers in HCC. On the 
other hand, several components of ERK (MAPK1, MAPK3, MAPKAPK2, MDM2, 
PRKCB1 and YWHAB), PI3K/AKT (PI3KCA) and Wnt (NLK) signaling and tumor 
invasion/metastasis (DERL1, MMP14, RUVBL2 SRC and THY1) made up the majority of 
genes in the liver cancer progression signature. These genes might likewise play an 
important role in HCC progression and could serve as markers for early liver 
tumorigenesis. Notably, the liver cancer progression signature comprises a group of 
genes participating in cell cycle and DNA damage and repair (MCM5, NBN, RRM2 and 
TK1) that have not been previously reported in human HCC. The most prominent gene is 




was initially known as a putative tumor suppressor protecting genome stability. However, 
recent findings have suggested that NBS1 is also an oncoprotein as it is overexpressed in 
several human cancers and leads to cell proliferation and transformation (Chen et al., 
2005; Hematulin et al., 2008). Some of the most critically regulated genes in these 
signatures have been confirmed by qRT-PCR from several individual lesions of 
transgenics (Table 3.3). Further investigations of these genes should be able to provide 
insights into liver tumorigenesis and likely provide new therapeutic targets for HCC. 
Collectively, using the constitutive krasV12 transgenics, this study presents the 
overall molecular mechanisms depicting KrasV12 liver tumorigenesis, which recapitulates 
many of the defined features of human liver cancer. Since HCC latency is relatively long 
and the penetrance of HCC in krasV12 transgenics remains less than 30% even in 9-
month-old fish, this model may not be suitable for anti-cancer drug screens. On the other 
hand, early Ras activation has been shown to cause premature lethality and act in a dose-
dependent manner to trigger cancer development. Therefore, further work has been done 
to apply the inducible gene expression systems (Emelyanov and Parinov, 2008) to control 
the induction time and expression level of the transgene (Section 3.2 and 3.3).  
 
4.3  Mifepristone-inducible krasV12 system as a potential for high-throughput 
anti-cancer drug screens 
Using mifepristone-inducible LexPR system (Emelyanov and Parinov, 2008), an 
important liver cancer model allowing for liver-specific, non-leaky, inducible, reversible 
control of EGFP-krasV12 expression in both larvae and adult transgenic zebrafish has 




different concentrations of mifepristone and a dosage-dependent induction of liver tumors 
was also observed. Interestingly, 100% of induced transgenics with 2 µM mifepristone 
developed full-blown HCC after 1 month of treatment, indicating an efficient tumor 
induction of this system. The inducible krasV12 expression by mifepristone also permits 
temporal control of liver tumor onset to prevent premature lethality, thereby allowing the 
propagation of stable transgenic models for large-scale studies. Indeed, these attributes 
overcome limitations present in the previous model which constitutively expressed the 
krasV12 oncogene (Section 3.1). If liver tumorigenesis rapidly progressed from 
hyperplasia to HCC, mifepristone withdrawal resulted in krasV12 inactivation leading to 
marked tumor regression and cancer cell death. Thus, these liver tumors were “krasV12 
addicted” for their continuous growth and survival. Observations in this study, together 
with other numerous evidences that support the concept of “oncogene addiction” derived 
from mouse models and cell lines of human cancer, providing a rationale for molecular 
targeted therapies against Ras signaling (Engelman et al., 2008; Singh et al., 2009; 
Weinstein, 2002). 
Recent therapeutic efforts to directly target mutant Ras have not been successful 
(Diaz-Flores and Shannon, 2007). Therefore, understanding effector pathways utilized by 
oncogenic Ras is fundamental to inhibiting Ras-induced liver cancer. For this reason, the 
relative importance of the two major pathways, Raf/MEK/ERK and PI3K/AKT/mTOR as 
downstream Ras targets which are necessary for oncogenic Ras driving signaling have 
been addressed in this study. Of note, the Raf/MEK/ERK and PI3K/AKT/mTOR 
pathways were found to be synergistically regulated by Kras throughout tumor 




model as EGFP-krasV12 overexpression from embryonic stage caused significantly 
enlarged liver which can be easily visualized under fluorescent microscope, the 
sufficiency of targeting these pathways using small-inhibitors were further tested in 
krasV12 transgenic larvae. The data clearly showed that inhibition of a single pathway led 
to only modest suppression of hyperplastic growth of liver. However, combined blocking 
of both Raf/MEK/ERK and PI3K/AKT/mTOR pathways efficiently inhibits krasV12-
induced liver tumorigenesis. This can be achieved either by dual targeting of MEK1/2 
and PI3K or MEK1/2 and mTOR for complete abrogation of both major Ras effector 
pathways. These results are consistent with previous reported that PI3K pathway 
activation renders KRAS mutated cancers insensitive to MEK inhibitors (Wee et al., 
2009) or vice versa (Carracedo et al., 2008). Furthermore, these observations parallel 
clinical findings that blockade of Raf/MEK/ERK and PI3K/AKT/mTOR pathways 
provide anti-tumoral effect in HCC and other Ras mutant tumors (Engelman et al., 2008; 
Newell et al., 2009). In this model, advanced liver cancer was marked by the 
development of mixed carcinoma, hepatoblastoma, malignant ascites or invasion of 
tumor cells into blood vessels or neighboring tissues (metastases) in transgenic fish. 
These signs and symptoms are also found in severe stages of human liver cancer 
(Lambrecht et al., 2011; Roncalli et al., 2010; Yamazaki et al, 2004). It is also interesting 
to note that the overall molecular mechanisms and gene signatures underlying krasV12 
liver tumorigenesis have been uncovered (Section 3.1). Based on effectors engaged by 
Ras, the rapid tumor onset and significant utilities of zebrafish system (Figure 4.2), the 
mifepristone-inducible krasV12 liver cancer model is envisaged to be useful for disease 





Figure 4.2 Tumorigenesis and tumor regression in the mifepristone-inducible krasV12 
liver tumor model. Driver/Ras-effector can be induced for overexpression of EGFP-
krasV12 with 2 µM mifepristone (RU486) at 4 weeks post-fertilization (wpf). Liver 
tumorigenesis progresses from hyperplasia (6 wpf) to carcinoma (8 wpf), hepatoblastoma 
(16 wpf), invasive cancer and malignant ascites (16-20 wpf). RU486 withdrawal results 





4.4  Mifepristone-inducible Cre/loxP regulating krasV12 system induces various 
liver tumors and closely mimics spontaneous cancer development 
In this study, a conditional regulation of krasV12-driven liver cancer zebrafish model was 
developed by combining Cre/loxP recombination and mifepristone-mediated activation. 
This approach enabled the control of disease onset to prevent developmental disorder and 
premature lethality caused by constitutive expression of krasV12, thus allowing easy 
maintenance and propagation of the compound transgenic lines. In addition, this liver 
cancer model led to earlier tumor onset, and altered tumor spectrum as compared with the 
other two models generated in this project (Sections 3.1 and 3.2). Notably, the 
appearance of broad liver tumors in induced Triple-Tg fish may reflect the mosaic 
activation of oncogenic krasV12 which also affects tumor incidence with only 65% of 
induced Triple-Tg fish at 1-month-old developing liver cancer. This can be explained by 
the earlier findings that only high level of krasV12 initiated liver tumorigenesis (Section 
3.1). These observations might support that short pulse treatment of chemical inducer 
frequently caused mosaic induction of transgene expression in binary and chemical-
inducible systems (Emelyanov and Parinov, 2008; Furth et al., 1994). Due to the 
variability, expression of the LexPR inducing Cre may differ among hepatocytes within 
the same liver, causing a mosaic pattern of Cre-mediated recombination. On the other 
hand, incomplete recombination at the locus containing transgene concatemers might 
explain why many induced Triple-Tg fish showed both mCherry and EGFP-labeled 
livers. Similar results have been noticed in other Cre/loxP-regulated transgenic models in 
which partial Cre-mediated excision always happened (Langenau et al., 2005; Feng et al., 




expression in subsets of cells within a tissue offers a unique opportunity to mimic 
spontaneous oncogenic mutations in humans (Jonkers and Berns, 2002). Strikingly, 
clonal proliferation of neoplastic cells expressing EGFP-krasV12 in normal-appearing 
liver can be visualized in the transgenic zebrafish generated in this study. By applying the 
same induction protocol, tumor induction rates were found to be higher in the group of 1-
month-old Triple-Tg fish than in the older groups. It is likely that the number of 
hepatocytes prone to malignant transformation was higher in young Triple-Tg fish. 
Moreover, high levels of Cre recombinase can cause toxic effects for proliferating cells 
(Schmidt-Supprian and Rajewsky, 2007). Thus, the older Triple-Tg fish may require 
different induction conditions to achieve a better tumor induction rate with minimal Cre 
toxicity. 
On the other hand, this model presents the first evidence that overexpression of 
oncogenic krasV12 led to various liver tumors including HCA, HCC and HB in transgenic 
zebrafish. Activation of Ras signaling through ERK pathway has been firmly established 
as major determinants of tumor cellular processes (Calvisi et al., 2006; Schmidt et al., 
1997). Recently, the development of HB has been found in Noonan syndrome patients 
with constitutively activated Ras/ERK signaling (Yoshida et al., 2008). These suggest the 
ubiquitous role of Ras signaling in the initiation and development of a wide range of 
hepatocellular neoplasias. The presence of HCCs in a hepatocellular-cell adenoma and 
mixed liver tumors were also observed in some human cases (Yamazaki et al, 2004; Burri 
et al., 2006). In this aspect, the current model has enormous potential for contributing 




transformation of HCA, as well as the evolution and correlation between different liver 
tumor types.  
 
4.5  Summary and conclusions 
In this study, efforts have been made to establish krasV12-induced liver cancer models in 
zebrafish by developing three different transgenic systems, including constitutive, 
mifepristone-inducible and mifepristone-inducible Cre/loxP recombination in regulating 
krasV12 expression. To date, these krasV12 transgenic zebrafish are the first in vivo models 
to address the molecular mechanisms underlying Ras-driven liver tumorigenesis which 
recapitulates typical hallmarks of human HCC, thus validating transgenic zebrafish in 
modeling human liver cancer. In general, krasV12-induced liver neoplasm progresses from 
hyperplasia to carcinoma and even invasive tumors which are transplantable into a new 
host. Although all of these systems efficiently induce liver tumors in transgenic zebrafish, 
each of them has their own advantages and disadvantages over others with respect to 
potential in future cancer research as summarized in Table 4.1. In the constitutive krasV12 
transgenic system, experimental results reveal that early Ras activation triggers liver 
tumorigenesis correlating the level of krasV12 expression, but causes premature lethality. 
HCC onset in this system is relatively long (9 months) and the tumor incidence is 
relatively low (approximately 30%), thus this transgenic line may not be practical for 
anti-cancer drug screening but could be used for chemical carcinogen screens as well as 
tumor enhancer screens to identify mutations that accelerate the onset of Ras-induced 
HCC. Moreover, the data obtained from this model provide a necessary and indispensible 




The second liver cancer model allowing for inducible expression of krasV12 in 
both larvae and adult transgenic zebrafish was generated by employing the mifepristone-
inducible LexPR system. A dosage-dependent control of the activation of KrasV12 
signaling by administrating different mifepristone concentrations was demonstrated and 
found 2 µM mifepritone efficiently induced a predictable and full-tumor penetrance 
(100%) within 1 month in transgenic zebrafish. Besides the robust liver tumor 
progression from hyperplasia to carcinoma stages, mifepristone withdrawal led to 
complete tumor regression via cell death due to the reversal of krasV12 expression. 
Strikingly, this phenomenon is consistent with the concept of “oncogene addiction” for 
tumor maintenance, providing a rationale for molecular targeted therapies in liver cancer. 
Although the signaling pathways downstream of Ras are immensely complicated by the 
high degree of cross-talk and dependency on factors, two major pathway effectors of Ras 
including Raf/MEK/ERK and PI3K/AKT/mTOR have been determined to be required for 
initiating and sustaining continuous tumor growth and survival. Indeed, the most 
convincing evidence comes from the small-inhibitor treatments using mifepristone-
induced EGFP-krasV12 transgenic fry with hyperplastic liver. These experiments 
indicated the pre-clinical finding that effective blocking of Ras mutant tumors requires 
sustained reduction in both Raf/MEK/ERK and PI3K/AKT/mTOR pathways. Notably, 
microarray and cross-species comparison analyses using the non-inducible model have 
uncovered conserved molecular mechanisms and gene signatures underlying krasV12 liver 
tumorigenesis in human and zebrafish. Understanding the multistep nature of HCC 
progression as well as crosstalk between Ras and different levels of other signaling 




liver cancer. Based on these findings and economical and high-throughput features of the 
zebrafish system, the mifepristone-inducible krasV12 liver cancer model will provide a 
potential platform for screens of anti-cancer drugs to target currently undruggable 
pathways such as Wnt/β-catenin signaling or several other simultaneous pathways in 
HCC development. On the other hand, the rapid tumor progression as well as the ease of 
embryo manipulation can also be exploited for identifying mutations in tumor suppressor 
genes or oncogenes which may delay or enhance krasV12 liver tumor onset and even cause 
early metastasis. This may be accomplished by overexpression of second transgene via 
microinjection in EGFP-krasV12 transgenics or application of mutagenesis approaches 
such as ENU treatment or retroviral integration. Since the oncogenicity of Ras is highly 
dependent on cellular context and intensity of Ras signaling (Guerra et al., 2003; 
Sarkistan et al., 2007), the mifepristone-inducible krasV12transgenic zebrafish can be used 
to assess these effects on Ras liver tumorigenesis.  
Human cancer is normally initiated by a sporadic event of in a single cell or group 
of cells, where clonal expansion from these cancer cells then results in tumor 
development. However, the constitutive and mifepristone-inducible systems provide a 
uniform expression of transgene in the liver and caused homogeneous transformation of 
hepatocytes in the whole liver. In this context, the third transgenic system via 
mifepristone-inducible Cre recombination could more faithfully mimic sporadic tumor 
formation in human due to partial Cre-mediated excision resulting in mosaic oncogene 
expression in subsets of cells within a transgenic liver. A broad and heterogeneous liver 
tumor spectrum was obtained in this system as compared with the others.  Importantly, 




to some rare human liver cancer cases, suggesting for the first time the ubiquitous and 
important role of Ras signaling in the initiation and development of a wide range of 
hepatocarcinogenesis. In this aspect, this system would be useful for mining novel 
genetic variants as well as evolution mechanism between different liver tumor types. 
Experimentally, this system requires only a short pulse of inducer treatment and it is 
more convenient and less laborious than the mifepristone-inducible system which needs 
the continuous presence of inducer to maintain the expression of krasV12. 
In conclusion, this project comprehensively demonstrates the generation and 
analyses of krasV12 driving liver tumorigenesis in different transgenic zebrafish model 
systems and also suggests a practical step-by-step experimental route in studying effect of 
a certain oncogene in cancer. The tight conservation of liver cancer-related pathways 
between fish and human underscoring that krasV12 transgenics are valuable liver cancer 
models in which studies of different transgenic systems describe their unique 
characteristics and utilizations as well as provide further insights into krasV12 liver 
tumorigenesis. High incidence and consistent pattern of cancer progression coupled with 
low maintenance costs allowed systematic study of tumor biology in transgenic zebrafish. 
Furthermore, the fluorescence-tagged liver tumors would enable live imaging of tumor 
progression and tumor-host interaction during transplantation. To reach their full 
potential in cancer research, it is critical that future studies should apply large-scale 
genetic and/or small-chemical screens using these zebrafish models as a platform for the 
identification of novel liver cancer genes as drug targets and promising anti-cancer 





Table 4.1 Comparison of the three krasV12-induced liver cancer models using 
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